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1I. Abstract
Diabetes is a complex metabolic disorder characterized by the failure to
maintain normoglycemia stemming from dysfunctional islet of Langerhans. It
is caused by an autoimmune destruction of insulin secreting β-cells in case of
type 1 diabetes (T1D), or non-insulin dependent diabetes, caused by lack on
insulin action and production in type 2 diabetes (T2D) and by insulin
insufficiency during pregnancy as in gestational diabetes mellitus (GDM). T2D
accounts for at least 90% of the cases of diabetes, although it may remain
undetected or at a pre-diabetic stage for several years. Thus, therapeutic
intervention to prevent the progression to T2D is a major goal to subside the
incidence of the disease and thus prevent further metabolic complications.
T2D is most commonly associated with obesity and thus peripheral insulin
resistance. In the face of insulin resistance there occurs an array of molecular
mechanisms, one of the major activator being inflammation. In serum,
adipose tissue, liver and pancreatic islets from T2D patients, pro-inflammatory
cytokines like IL-1β, CXCL10, TNFα, IL-6 have been detected and clinical
trials are initiated to prevent inflammatory action. In our study, we showed
anti-mouse CXCL10 antibody prevented diabetes progression; it improved
glucose tolerance, insulin sensitivity and restored glucose stimulated insulin
secretion in the HFD fed mice. CXCL10 antagonism also prevented
upregulation of pro-inflammatory cytokines, IL-1β, IL-6 and CXCL10 mRNA in
isolated islets, CXCL10 in adipose tissue and liver of high fat/high sucrose
diet (HFD) fed mice.
Dipeptidyl peptidase-4 (DPP-4) inhibitors are oral antidiabetics widely in use
for T2D treatment. The first agent of its class – sitagliptin – was approved by
the FDA in 2006 and since has been investigated for its direct effects on islet
function. The gluco-incretin hormones GIP and GLP-1 secreted by the
intestinal endocrine cells potentiate glucose stimulated insulin secretion but
are rapidly inactivated by DPP-4. We treated cultured human islets with a
diabetic milieu of high glucose, palmitate, cytokines and H2O2 in presence of
the DPP-4 inhibitor linagliptin. Linagliptin restored β-cell function and turnover,
via mechanism involving stabilization of secreted GLP-1 in islet supernatants.
Obesity induced insulin resistance requires expansion of β-cell mass to
maintain normoglycemia. There occurs a compensatory islet hyperplasia,
2progressing with altered islet vascularization and possibly angiogenesis,
inflammation and eventually leading to reduced β-cell mass, β-cell failure and
hyperglycemia. The molecular mechanisms involved in the concomitant
pathophysiology of islet endothelial cells in T2D has focused on effects
mediated by VEGF-A. In this study, we aimed to identify the regulation of and
the changes driven by the Angiopoietin/Tie angiogenic factors in islet
vascularization and function during the progression of T2D.
Ang-1 expressed by perivascular cells and β-cells and Ang-2 expressed by
endothelial cells exert their autocrine and paracrine effects via the cognate
receptor Tie-2, on the endothelial cells. Tie-2 signaling maintains quiescent
vasculature via constitutive Ang-1 expression whereas Ang-2 is known to be
in play in demand for angiogenesis or pathological stimuli involving
inflammation. Ang/Tie regulation and thus its role in diabetes and islet
vascularization is so far poorly understood.
Islet vessel area was increased in autopsy pancreases from T2D subjects,
compared to controls. Vessel markers Tie-1, Tie-2 and CD31 were
upregulated in mouse islets upon HFD feeding from 8 to 24 weeks. Ang-2 was
transiently upregulated in mouse islets at 8 weeks of HFD as well under
gluco-lipotoxicity in vitro in human and mouse islets, in contrast to its
downregulation with cytokine treatment. Ang-1 on the other hand was
oppositely regulated, with reduction under glucolipotoxic conditions and
upregulation by cytokine milieu. Modulation of such changes in Ang-2
expression by its overexpression or the inhibition of its receptor Tie-2 impaired
?-cell function at basal conditions but protected islets from cytokine induced
apoptosis in vitro. In vivo, β-cell-specific Ang-2 overexpression in mice
induced vascularization under normal diet but contrastingly hypovascularized
islets under HFD together with increased apoptosis and reduction of ?-cell
mass.
Our data show that increased islet hypervascularization is paralleled with
T2D. Maintaining physiological Ang-2 levels is important for islet
vascularization and ?-cell survival.
3II. Zusammenfassung
Diabetes ist eine komplexe Stoffwechselstörung, gekennzeichnet durch das
Versagen der Langerhans?schen Inselzellen, Normoglykämie aufrecht zu
erhalten. Dies wird vermutlich im Fall von Typ-1-Diabetes (T1D oder nicht-
insulin abhängiger Diabetes) durch eine autoimmune Zerstörung der Insulin
sekretierenden β-Zellen ausgelöst; durch einen Mangel an Insulin sensitivität
und –produktion im Fall des Type-2-Diabetes (T2D), und durch Insulin
insuffizienz während Schwangerschaft beim Schwangerschafts diabetes
(GDM). T2D betrifft mindestens 90% der Fälle von Diabetes, obwohl er über
mehrere Jahre unerkannt oder in einem prädiabetischen Stadium verbleibt.
Daher ist die therapeutische Intervention von extremer Wichtigkeit, um
Ausbruch und Fortschreiten von T2D und dessen schwere metabolische
Komplikationen zu verhindern.
T2D steht im Zusammenhang mit Übergewicht und einer peripheren
Insulinresistenz. Im Falle einer Insulinresistenz treten eine große Anzahl
molekularer Mechanismen auf, die durch subklinische Entzündungen aktiviert
werden. Bei T2D Patienten wurden im Serum, im Fettgewebe, Leber und
auch in den pankreatischen Inseln pro-inflammatorische Zytokine wie IL-1?,
CXCL10, TNF? und IL-6 gefunden. Klinische Studien wurden initiiert, diese
Entzündungsmarker und dessen Wirkung zu inaktivieren. In unserer Studie
konnten wir zeigen, dass der anti-Maus Antikörper CXCL10 ein Fortschreiten
von Diabetes verhindert; er verbessert die Glucosetoleranz, die
Insulinsensitivität und stellte die Glucose-stimulierte Insulinsekretion bei mit
fett- und zuckerreiche Diät (HFD) gefütterten Mäusen wieder her. Der
CXCL10 Antagonist verhinderte zudem eine Hochregulierung von pro-
inflammatorischen Zytokinen, IL-1?, IL-6 und CXCL10 mRNA in isolierten
Inseln, sowie von CXCL10 in Fettgewebe und Leber von HFD gefütterten
Mäusen.
Dipeptidyl-Peptidase-4 (DPP-4) -Hemmer sind orale Antidiabetika, welche
weit verbreitet im Einsatz für T2D Behandlung sind. Das erste Mittel seiner
Klasse - Sitagliptin - wurde von der FDA im Jahre 2006 zugelassen und wird
seitdem auf seine direkten Auswirkungen auf die Inselfunktion untersucht. Die
Inkretin hormone GIP und GLP-1 werden durch die intestinalen endokrinen
4Zellen sezerniert und potenzieren Glucose stimulierte Insulinsekretion,
werden aber schnell durch DPP-4 inaktiviert. Wir behandelten isolierte
humaniche Inselzellen mit einem diabetischen Milieu bestehend aus Glucose,
Palmitat, Zytokinen und H2O2, in Gegenwart des DPP-4-hemmers Linagliptin.
Linagliptin stellte die β-Zellfunktion und Überleben durch die Stabilisierung
von sezernierte GLP-1 in den Überständen von kultivierten Inseln wieder her.
Eine durch Fettleibigkeit induzierte Insulinresistenz erfordert eine Erhöhung
der β-Zellmasse, um Normoglykämie zu erhalten. Um den erhöhten
Insulinbedarf auszugleichen, kommt es zur Inselhyperplasie, mit veränderter
Gefäßbildung in den Inseln und möglicher Angiogenese und Entzündungen,
welche letztendlich zu einer reduzierten β-Zellmasse, β-Zellversagen und
Hyperglykämie führen. Die molekularen Mechanismen, die gleichzeitig in der
Pathophysiologie der Endothel- und Inselzellen in T2D beteiligt sind, werden
teilweise durch den Vasculären Wachstumsfaktor VEGF-A vermitteltet. Ziel
dieser Arbeit war es, die Regulierung der Insel-Vaskularisierung und Funktion
und die durch die angiogenen Faktoren Angiopoietin/ Tie bedingten
Veränderungen während des fortschreitenden T2D zu untersuchen.
Ang-1, exprimiert in perivaskulären und β-Zellen, sowie das in Endothelzellen
exprimierte Ang-2, üben ihre autokrine und parakrine Wirkungen über den
zugehörigen Rezeptor Tie-2 auf Endothelzellen aus. Der Tie-2-Signalweg
stabilisert ein physiologisches Blutgefäß system durch konstitutive Ang-1-
Expression, wohingegen Ang-2 eine Rolle bei Angiogenese und in
pathologischen Veränderungen, wie bei Entzündungen spielt. Über die Ang/
Tie Regulierung im Diabetes und deren Einfluss auf die Insel-Vaskularisierung
ist bisher wenig bekannt.
Meine Untersuchungen zeigen, dass das Blutgefäßvolumen in den Inseln im
T2D Pankreas im Vergleich zu nicht diabetischen Kontrollen erhöht ist. Die
Gefäßmarker Tie-1, Tie-2 und CD31 waren in Maus-Inselzellen nach 8-24
Wochen HFD Fütterung verstärkt. Ang-2 war nach 8 Wochen HFD Fütterung
in Maus Inselzellen, sowie in vitro unter glucolipotoxischen Bedingungen in
humanen und Maus Inselzellen erhöht, wohingegen es durch eine Zytokin-
Behandlung vermindert wurde.
Der Gegenspieler Ang-1 wurde entgegengesetzt reguliert, mit Verminderung
unter glucolipotoxischen Bedingungen und Hochregulation im Zytokinmilieu.
5Eine Veränderung der Ang-2-Expression durch Überexpression oder die
Inhibierung des Rezeptors Tie-2 führte zu einer Beeinträchtigung der ?-
Zellfunktion unter basalen Bedingungen, schützte die Inselnaber vor Zytokin
induzierter Apoptose in vitro. In vivo induzierte eine β-Zell-spezifische Ang-2-
Überexpression in Mäusen bei normaler Ernährung keine veränderte
Vaskularisierung, jedoch wurde in den HFD Mäusen eine Ang-2 induzierte
Hypervaskularisierung der Inseln, zusammen mit erhöhter Apoptose und
Reduktion der ?-Zellmasse beobachtet.
Unsere Daten zeigen, dass eine erhöhte Insel-hypervaskularisierung mit der
Entwicklung von T2D einhergeht. Die Aufrecherhaltung der physiologischen
Ang-2 Level ist entscheidend für  die Insel-Vaskularisierung und das
Überleben der ?-Zelle.
6III. Abbreviations
ADP Adenosine diphosphate
Ang Angiopoietin
ATP Adenosine triphosphate
CD Cluster of differentiation
DPP-4 Dipeptidyl peptidase-4
EC Endothelial cell
eNOS Endothelial nitric oxide synthase
ER Endoplasmic reticulum
FCS Fetal calf serum
FFA Free fatty acids
FGF Fibroblast growth factor
FTO Fat mass and obesity
GAD Glutamic acid decarboxylase
GDM Gestational diabetes mellitus
GIP Gastric inhibitory polypeptide
GK Goto-Kakizaki
GLP-1 Glucagon-like peptide-1
GLUT Glucose transporter
GSIS Glucose stimulated insulin secretion
HFD High fat diet
HUVEC Human umbilical vein endothelial cells
IA-2 Islet antigen-2
IAA Insulin autoantobodies
ICA Islet cell autoantibodies
ICSA Islet cell surface autoantibodies
IFN-γ Interferon-γ
IL-1β Interleukin 1β
7IPGTT/ITT Intraperitoneal glucose/insulin tolerance test
MCR4 Melanocortin receptor 4
ND Normal diet
NOD Non-obese diabetic
PC 1/3 Prohormone convertase 1/3
PECAM Platelet endothelial cell adhesion molecule
RT-PCR Real-Time Polymerase chain reaction
STZ Streptozotocin
T1D Type 1 diabetes
T2D Type 2 diabetes
TCF7L2 Transcription factor 7 like-2
TGF Tumor growth factor
TLR Toll-like receptor
TNF- α Tumor necrosis factor-α
VDF Vancouver diabetic fatty
VEGF Vascular endothelial growth factor
WHO World health organization
ZDF Zucker diabetic fatty
ZnT8 Zinc transporter 8
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A. Introduction 
This doctoral thesis mainly focuses on the role of islet vascularization via 
Angiopoietin/Tie angiogenic factors in maintaining ȕ-cell survival and function and 
thus, progression to T2D. Other two parts aimed to study, anti-inflammatory 
therapy in T2D, via CXCL10 antagonism and role of the DPP4 inhibitor, linagliptin 
on cultured islet survival and function. 
1. Diabetes 
Diabetes is a complex metabolic disorder to affect about 347 million people 
by 2014 worldwide according to WHO statistics and this number is predicted 
to double by 2030, with diabetes being the 7th leading cause of death. The 
most common symptoms for diabetes include excess urination (polyuria), 
excess thirst (polydipsia), unusual weight loss, fatigue, irritability and blurry 
vision. A diagnosis of 126mg/dL or higher fasting blood glucose levels are 
used to determine diabetes. Glycated haemoglobin, HbA1c levels 
determination is a more reliable test that blood glucose and value of ≥6.5% 
(48 mmol/mol) is considered diagnostic for diabetes. Diabetes types 1, 2 and 
3 are classified based on the cause, type 1 (earlier known as insulin-
dependent diabetes) is caused by autoimmune destruction of ȕ-cells, type 2 
(insulin independent diabetes) results from impaired insulin secretion and 
action and type 3 (gestational diabetes) develops during pregnancy due to 
failure to compensate for the increase in insulin demand. 
1.1 T1D 
Type 1 diabetes accounts for only 10% of the incidence of diabetes, it is 
much more dramatic and the mortality rates are much higher than other 
forms of diabetes. An absolute deficiency in insulin occurs due to a T-
cell–mediated autoimmune destruction of the ȕ-cells of the pancreas [1]. 
Although the main cause of this destruction is attributed to genetic 
factors, environmental factors like viruses are also involved. Most 
common incidence of T1D is among children and adolescents, although 
all age groups may be affected. More recently, the younger population 
acquires the disease in correlation with obesity [2].  
The disease develops as a result of a long moderate symptomless phase 
wherein the islet leukocyte infiltration occurs and chronic inflammatory 
response is elicited. This is followed by an acute diabetic phase with 
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absolute insulin deficiency T-cells have been found to respond to several 
autoantigens including peptides derived from insulin and glutamic acid 
decarboxylase (GAD) and killing ȕ-cells [3]. T1D immune markers involve 
a list of autoantibodies against such antigens as islet cell (cytoplasmic) 
autoantibodies (ICAs), islet cell surface autoantibodies (ICSAs), insulin 
autoantibodies (IAAs), islet antigen-2 (IA-2A) and zinc transporter 8 
(ZnT8) [4]. The initial steps involve presentation of ȕ-cell autoantigens to 
CD4+ T-helper cells on MHC class II molecules by macrophages and/or 
dendritic cells. The activated macrophages and CD4+ T-cells then 
release cytokines including interleukin (IL)-1ȕ, tumor necrosis factor 
(TNF)-α and interferon (IFN)–Ȗ, that attracts and activate CD8+ T-cells in 
the islets which subsequently destroy ȕ-cells by mechanisms like release 
of granzymes and perforin as well as by Fas-Fas-Ligand interactions [5]. 
1.2 T2D 
The major cause of type 2 diabetes is undoubtedly over nutrition and a 
sedentary lifestyle, leading to obesity. Obesity induced insulin resistance 
and the resultant/causative ȕ-cell failure leading to hyperglycemia is a 
hallmark of type 2 diabetes. 
Obesity induced insulin resistance involves several stages to T2D 
progression [6]. The foremost criteria being, peripheral tissue 
unresponsiveness, mainly proposed to be caused by mechanism post-
insulin receptor signalling, probably via the insulin receptor substrates. 
This increases the demand in insulin and causes a ȕ-cell mass 
expansion. The initial compensation in demand of increased insulin is 
fulfilled by simply higher insulin secretion and this is followed by an 
expansion of ȕ-cell volume or mass by proliferation. The nutritional 
overload in-turn causes a ȕ-cell overwork and often -cell failure due to 
metabolic or oxidative stress and additionally an inflammatory response, 
leading to ȕ-cell death [7, 8]. 
Such -cell failure most likely occurs through genetic predisposition [9]. 
The heritability of the disease is estimated to be 40-80% of the total 
susceptibility accounting for the cause of T2D. No single gene may be 
responsible for this heritability but the predisposition may be polygenic in 
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nature. The genes may be directly involved in insulin secretion, e.g. 
KCNJ11 – encoding part of ȕ-cell K+-ATP channel, or insulin action [10], 
IRS-1 – insulin receptor substrate or ȕ-cell proliferation [11]. A recently 
published genome-wide association study of obesity related traits shows 
fat mass and obesity-associated (FTP) gene, melacortin receptor 4 
(MCR4)  and transcription factor 7-like 2 (TCF7L2) having the strongest 
association with the disease [12].   
1.2.1 Islet inflammation in T2D  
T2D onset is clearly seen only when ȕ-cell failure occurs in the face of 
insulin resistance though the initial stages of ȕ-cell functional impairment 
have not been widely investigated. More and more evidence suggest a 
role for chronic islet inflammation playing a significant role in ȕ-cell 
dysfunction and failure in T2D [13-15] (Fig.1). An elevated number of islet 
associated macrophages are seen with increased expression of IL-1ȕ 
and depletion of these macrophages improves glucose tolerance in high 
fat diet fed mice. IL-1ȕ antagonism, by a monoclonal antibody improves 
glycemia and ȕ-cell function in diet induced obesity [16], reduced 
hyperglycemia and tissue inflammation in GK rat [17]. Elevated levels of 
IL-6 and IL-1ȕ are seen in islets by high fat diet feeding [18]. Clinical trials 
targeting inflammation in T2D, mainly via IL-1ȕ blockade, showing 
glycemic control and no adverse effects with drugs, have now gained 
momentum [19]. TNF antagonism is also has also shown positive results 
although lack of long-term treatments are lacking to prove its beneficial 
role in T2D prevention at the moment.    
The role of chemokines involved in T2D progression also comes from 
studies that found elevated levels of CXCL10/IP-10 in plasma associated 
with type 2 patients [20]. In the face of hyperglycemia and hyperlipidemia 
a strong peripheral tissue inflammation is elicited, with TLR4 being one of 
the major immune receptors involved in the adipose tissue and liver [21, 
22]. Elimination of the receptor showed attenuation of a pro-inflammatory 
state in diabetes [23]. CXCL10 was shown to impair mouse and human 
islet function and induce ȕ-cell apoptosis via the TLR-4 [24]. In this study, 
we have used an antibody to CXCL10 in mice kept on high fat/ high 
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sucrose diet feeding for 16 weeks and investigated effects on glycemia 
and peripheral tissue inflammatory status (manuscript in appendix). 
 
 
Figure 1: Proposed mechanism of IL-1β in islet inflammation in T2D 
Gluco and lipotoxicity, and deposition of islet amyloid induce expression of IL-1ȕ and 
islet associated macrophages in TβD. This in turn induces ȕ-cell dysfunction and 
apoptosis. IL-1ȕ blockade improves glycemia and preserved islet function by 
abrogating ȕ-cell apoptosis and maintaining ȕ-cell mass [25].  
 
Although, T2D is characterized by interplay of several organs and secreted 
factors in its progression the ȕ-cell failure remains central in its ultimate cause. 
Thus, it is important to look at the islet structure and anatomy.  
 
1.3 Pancreatic islet structure and vascularisation 
The pancreatic islets of Langerhans comprise the endocrine region, one part of 
the glandular organ - pancreas; with the exocrine region forming the other part 
(Fig.2a,b). The exocrine portion is mainly composed of acinar cells and is 
responsible for the secretion of digestive enzymes like trypsinogen and 
chymotrypsinogen. The islets of Langerhans can be described as highly 
vascularised mini-organs made of the following endocrine cells and their 
hormones – α-cell; glucagon, ȕ-cell; insulin, į-cells, somatostatin, PP-cells; 
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pancreatic polypeptide and İ-cells; ghrelin (Fig.2). The islets comprise of 1-2% of 
the total pancreatic mass but are provided with 10-15% of the blood supply [26]. 
Thus, they are in close connection with the endothelial cells and the surrounding 
extracellular matrix, forming a specialized capillary network serving the tight 
regulatory role of islets in glucose sensing and homeostasis (Fig.2c,d). The islet 
function is regulated by neural, paracrine as well as endocrine signals and the 
islet vascular system maintains the intercellular communication between the endo 
and exocrine pancreas and to multiple tissues.  
A peek into the vascular anatomy of the pancreatic islet reveals that each islet is 
supplied by 1-5 arterioles branching into capillaries forming a spherical 
framework like that of a glomerulus [27]. Differences in mouse and human islet 
cell- and angio-architecture have remained controversial despite several 
morphometric analyses. The issues at hand have been the proportion of ȕ-cells in 
islets, their mantle/core distribution within the islets and lastly the proximity of 
different cell types to the blood vessels. A recent study by Bonner-Weir et al [28], 
elegantly re-assessed what is known about the islet morphology and added their 
observation; that blood vessels penetrate non-random clustered ȕ-cells at the 
islet core in human islets. They also dismiss any major differences in mouse and 
human islet architecture, although the composition may vary within a pancreas. 
Islet microvasculature holds significant importance to functional 
compartmentalization of islet depending on the blood flow [29]. This, direction of 
the blood flow could determine the intraislet interactions. As far as islet 
microvasculature is concerned there are two schools of thought, one stating a 
lack of mantle/core distribution of insulin, glucagon or somatostatin 
immunoreactive cells and thus, the vessel penetration also being random and not 
ȕ-cell related [30, 31]. The other conclusion being, ȕ-cells occupy a core position 
and α-cell at the mantle, with islet vessels penetrating the islet having a close 
proximity to cells at the core [32]. Bonner-Weir et a.l report a rosette pattern of ȕ-
cells falling adjacent to blood vessels recently described in human islets and 
previously in rat islets [28, 33]. 
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Figure 2: Pancreas and islet vascularisation 
(a) The pancreas, located beneath the stomach, connected at the duodenum. (b) Islets 
of Langerhans, small clusters embedded in the exocrine acinar tissue. Islets mainly 
constituted of ȕ-cell core, and α- and į- cells, supplied with one or more small arterioles 
that then break into capillaries. (c) The endocrine cells are closely connected to 
capillaries with only a thin basement membrane separating them. The distinct secretory 
granules enable easy release into the blood stream. (d) Part of ȕ-cell showing secretory 
granules exocytosis [34] 
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1.4 Islet function: Insulin secretion and action 
ȕ-cells constitute the majority (65-80%) of the islet cells and secrete insulin in 
response to glucose which increases uptake and storage of glucose, fatty 
acids and amino acids by its actions on liver, muscle and adipose tissue. It 
also inhibits glucose production in the liver. Insulin is a 51 amino acid peptide 
hormone which is initially synthesized as preproinsulin on the ribosomes of 
rough endoplasmic reticulum and processed into proinsulin, which further 
breaks down to insulin and C-peptide [35](Fig.3). Insulin is secreted by ȕ-
cells in response to glucose in a pulsatile biphasic pattern with its release into 
the portal vein [36]. Glucose enters the ȕ-cell via GLUT2 transporters and is 
phosphorylated by glucokinase and enters glycolysis. The increased rate of 
glucose catabolism raises [ATP/ADP], causing the closing of ATP-gated K+ 
channels in the plasma membrane[37]. The reduced efflux of K+ depolarizes 
the membrane, thereby opening voltage-sensitive Ca2+ channels in the 
plasma membrane. The resulting influx of Ca2+ triggers the release of insulin 
by exocytosis. Persistent glucose metabolism in the ȕ-cells generates a 
number of intracellular signalling cascades which then in turn stimulate 
insulin gene transcription and mRNA translation. Stimuli from the 
parasympathetic and sympathetic nervous systems also stimulate and inhibit 
insulin release, respectively. Although intracellular Ca2+ seems central in 
insulin exocytosis, there are physiological instances when there is no further 
rise in Ca2+ but insulin secretion rises, in part due to incretins like 
acetylcholine, GLP-1, GIP or free fatty acids. 
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1.4.1. Incretins in insulin secretion 
The gluco-incretin hormones GIP and GLP-1 are secreted by the 
intestinal endocrine cells and have well established effects on 
potentiation of glucose stimulated insulin secretion [39](Fig.4). In 
addition, extrapancreatic actions of GIP and GLP-1 are important in 
physiological regulation of glucose and energy homeostasis. GLP-1, but 
not GIP is known to maintain this potentiating capacity even in patients 
with type 2 diabetesand has been a major therapeutic target since. 
Several GLP-1 analogues or inhibitors of the enzyme that degrades it are 
now commonly used in the clinic and ever evolving. GLP-1 and GIP both 
have also ȕ-cell differentiating [40], proliferating [41] and protect from 
cytokine induced 16poptosis [42]. GLP-1 or exendin-4, a long-acting 
agonist both increased ȕ-cell mass in pancreatectomized rats [43], db/db 
mice had improved glycemia with reduced HbA1c [44] and protected 
from diabetes with increased pancreatic insulin content in STZ injected 
rats [45]. GLP-1 or exendin-4 treatment has been shown to be prevent or 
at least markedly reduce each form of ȕ-cell apoptosis; TNFα induced 
[15], under glucolipotoxicity [13] or under ER stress by activating the 
unfolded protein response [46].  
GLP-1, in its biologically active form is lower than the total GLP-1 found 
in the plasma, and is just 10-20% [47]. This indicates that GLP-1 is a high 
affinity substrate for a ubiquitous exopeptidase dipeptidyl peptidase-4 
(DPP-4) DPP-4 inhibitors are now a well established line of drugs in the 
clinic for diabetic medications. Beneficial effect of DPP-4 inhibitors are 
not only restoring normoglycemia [48] but also restores ȕ-cell survival 
and neogenesis in the rat streptozotocin model [49] as well as in the VDF 
Zucker rats [50]. 
We investigated the mechanism of direct effects of the DPP-4 inhibitor, 
linagliptin on ȕ-cell survival and function in isolated human islets 
(appendix) [51].  
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Figure 4: Incretins and glycemic control 
GLP-1 and GIP are released by intestinal cells upon ingestion of food, which 
then act on the beta-cells to potentiate glucose-stimulated insulin secretion 
which regulates peripheral glucose uptake in the skeletal muscle and reduces 
hepatic glucose production. DPP-4 is a ubiquitously expressed enzyme which 
acts on GLP-1 and GIP to inactivate them, lowering GLP-1 insulin secretion 
efficacy. Adapted from [52]. 
 
 
Islet vasculature forms a functionally and structurally significant part of 
the islet indicating a need for a good understanding of its regulation in 
healthy and diabetic conditions. Thus, we will now look at the relevant 
aspects of the vascular system and focusing on its significance for the 
islets.    
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2. Vascularisation 
The vascular system is an organ system consisting of blood and lymphatic 
vessels - the arteries, veins and capillaries, carrying oxygen and nutrients to 
and from the tissues. The blood vessels are formed by the cellular lining of 
endothelial cells, that don’t merely form a barrier between the blood 
circulation and target tissues but are now known to be involved in a vast 
range of signalling activities. The vascular system is thus a multifunctional 
system, playing a vital role in physiology and pathology. 
Vascularisation comprises of two distinct processes – vasculogenesis; the 
formation of new blood vessels from primitive stem cells, that occurs mainly 
in the early embryogenesis, and angiogenesis; the formation of vessel from 
pre-existing capillaries. It may occur by sprouting; where mature ECs 
proliferate and migrate to form new vessels or intussusceptive, occurs by 
splitting vessels by invasion of interstitial tissue [53] (Fig.5a,b). Though the 
blood vessels on the whole play a common role in the wide spectrum of 
tissues, each organ vasculature is characterised by a specialized structure 
and function. This structure and function define the blood vessels; whether 
they have a vascular, lymphatic, large vessel or a capillary fate. The 
arterial/venous character of endothelial cells is decided early during 
embryogenesis by genetic factors whereas angiogenesis is regulated mostly 
by physiological stimuli and its molecular signalling cascade [54] (Fig.5c,d).  
 
 
 
 
 
19 
 
  
Figure 5: Development of the vascular system and angiogenesis 
Vessels are formed by vasculogenesis during the embryonic development from the 
mesoderm to form the primary plexus (a) Angiogenesis may occur by 2 types; 
sprouting or intussesception by mainly VEGF or TGFȕ (b) Pathologies cause vessel 
reorganization involving pericytes and Ang-2/Tie-2 and PDGF-BB (c) Arterial and 
venous fate depend on expression of and regulation by Notch and ephrin pathways 
[55]  
 
2.1 Blood vessel structure and heterogeneity 
The blood vessel consists of distinct layers of cells and membranes; the 
internal endothelium is covered by a basement membrane, created by 
various matrix proteins secreted by the endothelial cells. The basement 
membrane is covered by smooth muscle cells sandwiched between elastic 
membranes in thicker vessels. Blood vessel structure is acutely regulated by 
the innervations surrounding all these layers and is mainly responsible for 
modulation of organ blood flow. The capillaries that are closest to contact 
with specific organ cells consist of the endothelium and a layer of pericytes, 
which together creates the extracellular matrix surrounding the capillary. 
Capillary endothelial cell structure and function differ depending on the 
environmental cues, various metabolites, growth factors and cytokines, 
oxygen tension and mechanical forces.  [54]. ECs of different organs contain 
not only distinct subcellular structures, but are also metabolically and 
physically dynamic regulating blood flow, vessel permeability, thrombosis, 
thrombolysis, angiogenesis and immunity [56]. Another proof of endothelial 
heterogeneity among tissues is described by differences in their gene 
expression and antigen composition [57]. 
 
20 
 
2.1.1 Morphological heterogeneity of the endothelium 
Endothelium is continuous or fenestrated, fenestrae (with or without 
diaphragm), caveolated or with transendothelial channels [58]. The 
continuous and non-fenestrated endothelia lining the blood and lymph 
vessels, capillaries (of skin, lungs, kidney, muscles, brain) and chambers of 
the heart form an uninterrupted barrier between blood and tissues. 
Continuous fenestrated endothelium on the other hand, with pore sizes ~70 
nm are organised in planar clusters and are a characteristic of capillaries of 
the endocrine gland (pancreas, pituitary etc.), digestive tract mucosa and 
peritubular part of the kidney. The discontinuous endothelium of the liver 
sinusoidal endothelial cells, spleen and bone marrow, lack a basement 
membrane and are instead caveolated. 
2.1.2 Heterogeneity in phenotype and markers 
Apart from morphological differences, post-capillary endothelial cells express 
specific markers depending on the vascular bed in which they dwel [54]. For 
example, lung endothelial cell adhesion molecular-1 is in lung ECs, tPA is 
highest in brain and glomerular, sinusoidal and lymphatic ECs are negative 
for vWF [59]. Even PECAM-1, the most frequent EC marker, which controls 
neutrophils and their migration as well as endothelial monolayer stabilisation, 
is also expressed on trophoblasts and monocytes.VE-cadherin is restricted to 
arteries, arterioles and capillaries, with extremely low expression in venous 
ECs[60]. 
In addition to their heterogeneic morphology and marker expression, ECs 
display an enormous diversity in function, making them indispensible in 
organism homeostasis. Quiescent endothelium presents anti-adhesive, -
coagulant and vasodilating properties in contrary to activated ECs, which in 
addition have elevated transmigration of immune cells[61]. One of the 
distinguishing roles of activated ECs is their function as mediator of the 
inflammatory cascade. Endothelial cell permeability dysfunction is a 
consequence of a severe inflammatory state, often leading to oedema. ECs 
form the first barrier for immune cell infiltration and thus play an important 
role in adaptive and innate immunity. Immune cell recruitment is mediated by 
VEGF and Ang, via cytokines like TNFα, Iδ-6 and IL-1ȕ [62]. Further, 
leukocyte attachment and rolling are mediated by upregulation of P-selectins, 
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and transmigration by E-selectin. Integrins and endothelial cell adhesion 
molecules (ICAM-1 and VCAM-1) are then upregulated and the final 
transendothelial migration is supported by disassembly of the VE-cadherin 
complex at tight junctions [63]. 
Regardless of the extent and type of organ vascularisation, the vasculature 
relies on expansion of networks to fulfil the demands in the state of tissue 
pathology. 
2.1.3 Islet endothelial cells 
As stated above, there exists great endothelial cell heterogeneity between 
capillaries of different organs. Islet endothelial cells are highly fenestrated 
and surrounded by a basal lamina of no more than 500 nm prior to contact 
with ȕ-cells [64]. Modulation in islet vasculature via VEGF-A deficiency has 
shown the crucial role of the high vessel density and fenestrae in controlling 
the secretory function of islet. One of the first studies showing a direct role of 
endothelial derived molecules in islet development was by Lammert et al [65]. 
Blood vessel endothelium induces insulin expression in the mouse embryonic 
tissue in vitro and the removal of the dorsal aorta in Xenopus laevis embryos 
failed to induce insulin expression in vivo. Yet another proof of endothelial 
role in islet development was a study showing early dorsal pancreatic 
development, via induction of pancreatic transcription factor Ptf1a [66]. They 
also showed influence of endothelial cells on insulin and glucagon gene 
expression. 
Nonetheless, be it simply via the blood flow regulation or intraislet 
interactions the islet capillary plays a crucial role in islet function and thus 
glucose homeostasis. 
  
2.2 Islet perfusion and vascularization in diabetes 
One of the physiological ways of regulating islet function and secretion is 
modulation of islet blood flow. Islets are very densely vascularised mini-
organs, relying on fine tuning of islet perfusion in demand to insulin One 
of the early works of P.O. Carlsson in 1996 demonstrated via microsphere 
technique that islet blood flow rises with glucose administration without 
affecting the whole pancreatic blood flow [67]. They also showed such a 
rise in islet blood flow in pathological situations as in obese ob/ob mice 
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but actually lower blood flow compared to lean controls, when normalised 
to the islet weight, thus showing poorly perfused bigger islets. This may 
contribute to the impaired insulin secretion observed in such pathological 
conditions.  
Insulin exerts biological anabolic action on liver, adipose tissue and 
skeletal muscle affecting glucose, lipid and protein metabolism through 
insulin receptor signalling and GLUT4 translocation [68]. 60% of the 
insulin is cleared by the liver via the insulin secretion from the portal vein 
where its concentration is 3 fold higher than the plasma concentration. 
Hepatic gluconeogenesis is thus inhibited and glycogen storage 
promoted. In the skeletal muscle glucose uptake enables glycogen 
storage and in adipose tissue fat breakdown is suppressed and synthesis 
promoted. The endothelial insulin receptor signalling was recently shown 
to directly regulate islet insulin secretion in vivo via the insulin receptor 
substrate-2[69]. There is an increased demand in insulin in response to 
over-nutrition like in obesity or a lack of insulin occurs in an autoimmune 
response causing ȕ-cell failure, both eventually leading to chronic 
hyperglycemia and thus diabetes 
 
Islet microangiopathies were shown in a type 1 diabetic model, alloxan-
treated male Wistar rats way back in 1989 with following observations; 
acellular capillaries, basement membrane thickening, perivascular edema 
and endothelial cytoplasmic bulging [70]. The same group studied in 1995 
the microvasculature in a mouse model of T2D, db/db mice [71]. Electron 
micrographs from these pancreas revealed “capillary scarcity, increase in 
the mean and diversity of capillary size, pericapillary edema and fibrosis, 
hypertrophy of pericyte and abundance of actin-like microfilaments and 
luminal irregularity”, most characteristics indicating hyper-perfusion. 
Hyperglycemia mediated increase in islet blood pressure was soon 
discovered in diabetic GK rats by Carlsson et al[72]. The islet blood flow 
or perfusion on the other hand in obese-hyperglycemic (ob/ob) mice was 
increased compared to lean controls but reduced upon correction with 
islet weight [67]. Both studies implicated a role of islet vessels in the 
pathogenesis and advancement of diabetes. 
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It has been long debated whether more vascularisation is better or worse for 
islet function and the answer seems to be context dependent. Higher blood-
perfused native islets with improved function are better revascularised upon 
transplantation but the very same group of islets are more prone to cellular 
stress [73]. There are almost equal and opposing views about how islet 
vessels behave in response to ȕ-cell mass expansion; if islets are hypo or 
hypervascularised in eventual loss of ȕ-cell failure. Only a recent study by 
Brissova et al [74] have clearly shown a higher islet vessel density in T2D 
islets associated with amyloid deposition.  
90% of all patients with diabetes are affected by type 2 diabetes with 
cardiovascular disease dependent deaths being responsible for 50-80% of 
the mortalities. Microvascular complications may occur in patients after acute 
metabolic distress cause by hyperglycemia, affecting kidneys, eyes and 
nerves. Macrovascular detrimental effects like myocardial infarction can be 
seen after a prolonged period of hyperglycemia. Peripheral tissues, adipose 
and skeletal muscles seem to have lower vessel density in response to 
obesity [75, 76]. Several studies focusing on angiogenic factors in regulating 
islet vasculature in diabetes have now brought into focus the underlying 
mechanism of how islet vessels respond in demand of increased insulin and 
expansion to ȕ-cell mass. In a HFD mouse model, impaired islet 
vascularisation was redundant to ȕ-cell mass expansion [77] shown by ȕ-cell 
VEGF mutant mice. An increase %vessel/islet area upon 4 months of HFD 
feeding [78] associated with increased VEGF content or no change in vessel 
density (though vessel area/islet area increased) but dilation in response to 
ȕ-cell mass expansion [79] in ob/ob, GLUT4+/- and 4 months HFD fed mice.  
VEGF-A is one of most widely studied in context of diabetes, in T1D for islet 
vascularisation in transplanted grafts and in T2D for islet angiogenesis in 
response to obesity. VEGF-B improves insulin sensitivity in obesity and anti-
VEGF-B therapies are suggested to improve the diabetic phenotype [80].  
It remains to be investigated to what extent angiogenesis contributes to ȕ-cell 
failure and thus progression to T2D.  
.  
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2.3 Angiogenesis and angiogenic factors 
Angiogenesis may be physiological, as in the female reproductive system or 
pathological. There’s a wide range of pathological angiogenesis states from a 
simple process like wound healing to cardiovascular diseases, diabetes and 
cancer. The potential of angiogenesis having therapeutic value has 
stimulated great interest in the past 40 years[81]. One of the major 
applications of angiogenesis research involves developing anti-angiogenic 
treatments for tumour growth inhibition [82]. In order to understand the 
targets of angiogenesis for therapeutic applications we need a thorough 
understanding of the steps and its molecular mechanisms. Angiogenesis; 
whether growth or regression, involves a series of well co-ordinated events, 
with autocrine or paracrine signals on endothelial cells. Hypoxia is one of the 
key factors initiating angiogenesis to overcome the oxygen depletion and 
starvation [83]. Angiogenesis is a multi-step process with distinct stages 
(Fig.6); firstly, the stimulation of the endothelial cells by angiogenic factors. 
Angiogenic factors classically involved in this process are bFGF, VEGF and 
Angiopoietins acting on their receptors FGFR, VEGFR and Tie-2, 
respectively[84-86]. They activate endothelial cells for proliferation, survival 
and migration. Secondly is the degradation of the basal lamina composed of 
lamins, collagens and proteoglycans, mainly by matrix-metalloproteinases 
followed by EC migration and growth in order to form vessel tubes by 
adhesion molecules like integrins [87]. Remodelling occurs again by a 
complex interplay of MMPs to dissolve the extracellular matrix. Once, the 
lumen is formed, the pericytes migrate to the vessel to stabilise them mainly 
by the Tie-2-angiopoietin-1 signalling and TGFȕ [88]. 
In the past decades, FGF, VEGF, HGF, EGF and Angiopoietins have been 
described to play distinct roles in each step of angiogenesis and pathologies. 
The VEGF family of angiogenic factors contains more than seven members, 
with VEGF-A playing the most significant role, binding to VEGFR1 and 
VEGFR2 receptors regulating angiogenesis and permeability as well as 
vasculogenesis [84]. On the other hand, Angiopoietin/Tie maintains the 
quiescent vasculature and endothelial cell survival [86]  
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Figure 6: Steps involved in angiogenesis 
Angiogenesis initiates with conversion of quiescent EC to activated state and 
dissociation from pericytes. The MMPs and uPAR signalling dissolved the basal 
lamina and primes ECs for proliferation and migration. In the next step is the lumen 
formation regulated by integrins and cell-cell junctions, followed by a final maturation 
and pericyte migration to the blood vessel tube [89] 
 
2.3.1 Angiopoietin/Tie 
The Ang/Tie family of angiogenic factors consists of the receptors Tie1 and 
Tie2 (also known as TEK) and the ligands angiopoietin-1 (Ang-1), 
angiopoietin-2 (Ang-2) and the mouse/human interspecies orthologs Ang-
3/Ang-4, respectively. 
2.3.1.1 The Tie Receptors 
Tie-1 and Tie-2 genes, on mouse chromosome 4 encoding the Tie receptors 
discovered in 1993, were found to be endothelial specific tyrosine kinase 
receptors of crucial importance to the vascular system[90]. Both the receptors 
(46% identity) consist of three extracellular epidermal growth factor-like 
repeats, two immunoglobulin-like domains and three fibronectin type III 
repeats. The cytoplasmic tail consists of split tyrosine kinase domains. The 
function of the Tie receptors in vascular integrity and survival was established 
even before the discovery of their ligands. They were shown to be expressed 
also on some hematopoietic cell lineages in addition to endothelial cells[91]. 
The Tie receptors are not required for initial differentiation of endothelial cell 
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lineage but are essential at later stages for maintenance of the 
microvasculature. Tie1deletion shows normal vascular development upto 
E13.0 but then causes loss of endothelial cell integrity and death of embryos 
at E14.5[92, 93]. Tie2mutants resemble the Tie1mutants but they die earlier 
at embryonic day 9.5[94]. Though Tie-1 and Tie-2 seem to be functionally 
similar, Tie-1 is long known as an orphan receptor, but Tie-2 was 
deorphanized by the discovery of angiopoietins. Tie-1 exerts a weak kinase 
activity under normal conditions; itdoes not directly bind angiopoietins but 
modifies Tie-2 dependent intracellular signalling and can also inhibit Tie-2 
ligand binding by Tie-1 ectodomain cleavage [95]. Tie-1 seems to play a role 
in endothelial inflammatory gene expression [96] Tie-1 exerts 
proinflammatory properties; its overexpression induces inflammatory gene 
expression in endothelial cells [97]. 
2.3.1.2 The Tie Ligands 
Angiopoietinsare ~75 kDa proteins made up of amino-terminal coiled-coil 
domain responsible for ligand homo-oligomerization and carboxy-terminal 
fibrinogen domain containing binding sites for Tie-2 [98]. Ang-1 and Ang-2 
have been the most widely studied and Ang-1, mainly expressed by pericytes 
is the classical agonist of Tie-2, inducing autophosphorylation of the kinase 
domain and thus regulating intracellular pathways, i.e. cell proliferation, 
survival, sprouting and migration [99]. Ang-2, expressed mainly by 
endothelial cells and some smooth muscle cells was classically known to 
antagonise Tie-2 signalling with a similar affinity asAng-1. It also induces Tie-
1 signalling in a context-dependent manner [100-102]. Ectopic expression of 
Tie-2 in non-endothelial cells as well as high concentrations of Ang-2 is 
known to induce Tie-2 signalling activities similar to Ang-1. This was 
consistent with the finding of Ang-1  [99] and Tie-2 deficient [93] mice having 
similar phenotypes to Ang-2 overexpressing mice [103]. Unlike constitutive 
Ang-1 expression, Ang-2 expression is tightly regulated and strongly 
expressed during angiogenesis and inflammation [104, 105]. It is proposed to 
regulate angiogenesis in an autocrine manner whereas it inflammatory 
effects could be paracrine via the immune cells. Ang-1 reduces expression of 
cell adhesion molecules [106] and Ang-2 on the other hand promotes 
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vascular leakage and inflammation [107] (Fig.7). Thus Ang-2 upregulation 
had been correlated to several inflammatory disorders from sepsis to cancer.     
 
 
 
 
Figure 7: Angiopoietin/Tie-2 signalling    
Ang-1 consitutively expressed by pericytes maintains endothelial survival via 
P1γK/Akt and prevents inflammation via NFκB inhibition. Ang-2 is induced upon 
stimuli like hypoxia and cytokines like TNF, and released from the Weibel Palade 
bodies to block Ang-1 binding to Tie-2. It induces inflammatory pathways and 
upregulates cell adhesion molecules and destabilizes the vessel by pericyte dropout 
www.snipview.org  
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2.4 Aim of the thesis 
The beneficial role of Ang-1 in preventing diabetes-induced vascular 
complications has been extensively reviewed [108]. Ang-1 protects islets 
from cytokine induced apoptosis promoting islet function and 
revascularisation in transplanted islet grafts [109]. Circulating Ang-2 and 
sTie-2 levels have been associated with diabetic microangiopathies and 
HbA1c levels [110, 111]. Upregulating Ang-2 in islets transplanted to STZ 
treated mice was correlated with impaired vascularisation with lower islet 
vessel density and its inhibition improved glycemia in these mice [112]. 
Though some studies have shown roles of Ang-2 in islet vascularisation in 
developing tissue or basal conditions, not much is known about its role in islet 
vascularisation in T2D.   
Our aim was to identify if upregulated levels of Ang-2 impair islet 
vascularisation in TβD. Using ȕ-cell specific Ang-2 overexpressing mouse 
model and Ang-2 overexpression and downregulation in mouse and human 
islets in vitro we found protective and deleterious effects of Ang-β on ȕ-cell 
survival and function.  
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Islet angiogenesis has been suggested to influence β-cell survival and function in
progression to type 2 diabetes (T2D). Obesity induced insulin resistance requires
expansion of β-cell mass to maintain normoglycemia. Failure of the ?-cell to
compensate for the increased insulin demand as a result of a complex interplay of
genetic  and environmental factors, e.g. ongoing inflammation in the islets and
impaired vascular function, eventually leads to diabetes.
The molecular mechanism involved in the concomitant pathophysiology of islet
endothelial cells in T2D is mainly mediated via VEGF-A. In this study, we aimed to
identify whether there are changes in islet vascularization during the progression of
T2D, focusing on Ang/Tie angiogenic factors.
Islet vessel area was increased in autopsy pancreases from T2D subjects, compared
controls subjects. Vessel markers Tie-1, Tie-2 and CD31 were upregulated in mouse
islets upon HFD feeding from 8 to 24 weeks. Ang-2 was transiently upregulated in
mouse islets at 8 weeks of HFD as well under glucolipotoxic conditions (22.2mM
glucose, 0.5mM palmitate) in vitro in human and mouse islets, in contrast to its
downregulation with cytokine treatment (IL-1β, IFN-ɣ and TNF-α). Ang-1 on the other
hand was oppositely regulated, with reduction under glucolipotoxic conditions and
upregulation with cytokine milieu. Modulation of such changes in Ang-2 expression
by its overexpression or the inhibition of its receptor Tie-2 impaired ?-cell function at
basal conditions but protected islets from cytokine induced apoptosis.
In vivo, β-cell-specific Ang-2 overexpression in mice induced under normal diet but
contrastingly hypovascularized islets under HFD together with increased apoptosis
and reduction of ?-cell mass.
Our data show that increased islet hypervascularization is paralleled with T2D and
that maintaining physiological Ang-2 level is important for islet vascularization and ?-
cell survival.
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Introduction
Pancreatic islets are densely vascularized mini-organs constituting 1-2% of the
pancreatic mass but supplied by 5-15% of the pancreatic blood flow [1, 2]. The islets
are penetrated by a specialized endothelium with more highly fenestrated capillaries
than the exocrine tissue and with a unique basement membrane [3]. The laminin
isoforms are known to directly influence β-cell function and proliferation [4]. In their
remarkable study Lammert et al. showed that the islet endothelium sends inductive
signals to direct islet development, beyond merely serving the metabolic demand [5].
This suggests endothelium regulated islet survival.
Obesity induced insulin resistance is characterized by a compensatory increase in β-
cell function and mass. Although the ?-cell has the remarkable capacity to
compensate for the higher insulin demand, it often leads to ?-cell overwork and a
consequent loss of β-cell function and survival. Consequently, hyperglycemia and
type 2 diabetes (T2D) manifests. The role of islet angiogenesis during compensated
β-cell mass expansion and function has been highlighted in the ZDF rat, showing a
transient islet hypervascularization preceding β-cell failure [6]. Other studies have
revealed a dilation of pre-existing islet vessels in response to β-cell mass expansion
[7] or an indispensability of proper vasculature during β-cell mass and function
adaptation in response to high fat diet induced obesity in mice [8]. In contrast a
recent study shows that human islets present a higher vessel density in T2D, which
occurs together with amyloid depositions in areas of thicker capillaries [9]. Such
higher vessel area in T2D suggests that vessels, although they bring nutrients, which
are especially important in the ?-cell compensation state, may also be detrimental
through the delivery of inflammatory products from the circulation to the proximity of
the highly sensitive ?-cells. Variations in observation of the physiological relevance
of islet vessel density on islet function may be owing to variations in islet angio-
architecture within and between species. Human islets were found to have lower
vessel density than mouse islets [9] and whether islet capillaries favour proximity to
β-cells is yet an evolving debate [10, 11].
Islet angiogenesis is promoted by three major families of angiogenic factors;
vascular endothelial growth factors (VEGF), angiopoietins (Ang) and ephrins (Eph).
VEGF-A among the VEGFs, is the most highly expressed in the islet and the most
extensively studied in islet development and the diabetic patho-physiology. VEGF-A
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deficiency leads to a less dense and immature capillary network during embryonic
[12, 13] as well as postnatal islet development [14] and reduces insulin content and
secretion [15]. VEGF-A overexpression on the other hand, enhances islet
vascularization but impairs islet morphogenesis and β-cell proliferation [16, 17]. The
Ang/Tie family of angiogenic factors is so far poorly studied in the context of
diabetes. It consists of the ligands Ang-1,-2 and Ang-4 (its mouse orthologue Ang-3)
and the tyrosine kinase receptors Tie-1 and Tie-2. Ang-1 expressed mainly by the
perivascular cells and β-cells in mouse and human islets [14], is the agonist of Tie-2,
expressed by the endothelial cells. Ang-2 expressed by endothelial cells classically
antagonizes Tie-2 signaling [18]. It promotes vascular leakage [19] and is described
as the pro-inflammatory angiogenic factor [20, 21], mostly studied in tumor
vasculature. Ang-2 can also act as a context-dependent Tie-2 agonist [22, 23]. Thus,
Ang-2 is known as a ?multifaceted cytokine? involved in angiogenesis as well as
inflammation [24]. Adding to its ambiguity, Ang-2 has been considered as important
part of the vascular niche involved in liver regeneration [25]. A dynamic regulation of
Ang-2 by liver sinusoidal endothelial cells mediates hepatocyte proliferation by a
complex cross-talk via TGFβ-1, thus highlighting its capacity in regenerative
angiogenesis [26]. Tie-1 remains largely elusive in this system, though a co-
operative role of Tie-1 in Ang-1/Tie-2 signaling ranging to a prominent role in
vascular homeostasis has been indicated [27, 28].
Elevated levels of serum VEGF, Ang-2 and soluble Tie-2 have been associated with
T2D and vascular dysfunction [29, 30]. Hyperglycemia and free fatty acids ablate
Ang-1 mediated Tie-2 signaling in HUVECs [31] whereas Ang-1 protects islets from
cytokine induced apoptosis also in absence of Tie-2 and improves islet
revascularization post-transplantation [32]. In contrast, Ang-2 has been associated
with vascular defects under hyperglycemia [33]. While VEGF-A overexpression
increased vascularization near the islet cells and massively altered β-cell function,
proliferation and mass, ?-cell specific overexpression of Ang-1 or Ang-2 only slightly
impaired insulin secretion and glucose tolerance together with marginal altered
vascularization, islet mass and morphology [16]. The influence of diabetogenic
conditions was not tested in these studies.
The question still remains, whether diabetes progression is a result from altered islet
vascularization and whether an increased vascularization improves islet survival or
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rather promotes ?-cell loss through inflammatory signals brought by the vessels.
Therefore, in this study, we set to investigate the changes in islet vessels under
diabetogenic conditions together with the function of Ang-2 in islet angiogenesis in
the high fat diet induced diabetes mouse model.
Research design and methods
Animals
RIP-rtTAtg/tg (C57BL/6/CBA background) and Tet-O-Ang-2tg/wt (CD-1 background,
backcrossed with C57BL/6) mice were used to obtain β-cell specific Ang-2
overexpressing RIP-rtTAtg/tg ;Tet-O-Ang-2 tg/wt mice (kindly provided by A. Powers,
Nashville, TN). Briefly, we used the inducible “tet-on” (tetracycline regulated)
transgenic system to allow expression of Ang-2 under the rat insulin promoter (RIP)
by doxycycline (Dox; a tetracycline derivative). Male RIP-rtTA;Tet-O-Ang-2 and RIP-
rtTA littermate control mice between 8 to 10 weeks of age were given a normal chow
diet (ND) (Harlan Teklad Rodent Diet 8604 containing 12.2, 57.6, and 30.2% calories
from fat, carbohydrate, and protein, respectively; Harlan Teklad, Madison, WI) or a
high-fat high-sucrose diet (HFD) (“Surwit,” containing  58, 26, and 16% calories from
fat, carbohydrate, and protein, respectively; Research Diets, Inc., New Brunswick,
NJ)for 8, 16 or 24 weeks followed by islet isolation. The mice were provided with 1
mg/ml doxcycline in drinking water throughout the experiment with changes of water
every 2 days. Male and female C57BL/6, 8-12 weeks of age were used for islet
isolation and culture. All animals were approved by the Bremen Senate in agreement
with the §8 of the German animal protection law.
Metabolic tests
Intraperitoneal glucose tolerance test (IPGTT): Mice were fasted for 14-16 hours
overnight and injected intraperitoneally with 1g/kg body weight glucose(40%;
B.Braun, Melsungen, Germany) and blood glucose levels were measured at 0, 15,
30, 60, 90, and 120 minutes post injection.
Intraperitoneal insulin tolerance test (IPITT): Mice were fasted for 4 hours and
intraperitoneally injected with 0.75 IU/kg body weight of recombinant human insulin
(InsHuman Rapid, Aventis, Germany) and blood glucose was measure 0, 15, 30, 60
and 90 minutes post injection.
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Glucose-stimulated insulin release: Glucose stimulated insulin secretion test was
performed on mice after 12-14 hours overnight fasting and intraperitoneal injection of
2 g/kg BW glucose. Blood samples obtained from the retrobulbar plexus at 0 and 30
minutes post injection and the serum was used to measure insulin concentration
(Mouse ultrasensitive insulin ELISA, ALPCO Diagnostics, Salem, NH).
Islet isolation and cell culture and treatment
Mouse islets were isolated as previously described [34]. Briefly, islets were isolated
by 2 mg/ml liberase (Roche, Mannheim, Germany) injection into the pancreas and
digested for 10 minutes at 37 oC in a horizontal shaker. Islet were partly purified by
using a density gradient of Histopaque solution (1:1; 1077 and 1119, Sigma) and
further purified by hand-picking under a microscope in sterile conditions. Mouse and
human islets were cultured in extracellular matrix (ECM-) coated dishes (Novamed
Ltd., Jerusalem, Israel)[35] for 48 h through all experiments. For Ang-2
overexpression, islets from RIP-rtTA;Tet-O-Ang-2 and RIP-rtTA control mice were
maintained in 10 ug/ml doxycycline prior to and during treatments. Islets were
treated with diabetogenic conditions of glucolipotoxicity (22.2mM glucose+0.5mM
palmitate) or a cytokine milieu (2 ng/ml IL-1β, 1000U/ml IFN-ɣ and TNF-α) for 72 h.
MS-1 (ATCC CRL-2279), islet endothelial cell line (kindly provided by P-O Carlsson,
Uppsala, Sweden) was cultured in DMEM 5.5mM glucose/5% FCS media and
treated with glucolipotoxic (22.2mM glucose+0.25 mM palmitate) or a cytokine milieu
(2 ng/ml IL-1β, 1000U/ml IFN-ɣ and TNF-α) for 24 h. 100nM Tie-2 kinase inhibitor
(Calbiochem, MerckMillipore) was added in parallel to treatments.
Transfection and infection
Ang-2 or Tie-2 downregulation was achieved by using siRNA (ON-TARGETplus
siRNA, Dharmacon) in dispersed islets. Transfection was carried out as previously
described [36]. Briefly, islets were dispersed into smaller cell aggregates to increase
transfection efficiency with accutase for 5-10 minutes at 37 oC and then plated in
ECM-coated dishes. 100 pM siScr or siRNA was delivered with Lipofectamine 2000
(Invitrogen). Ang-2 overexpression was obtained with control Adenovirus-GFP or
Adenovirus-Ang-2 (kindly provided by H. Augustin, Heidelberg, Germany) 50 MOI for
4 h.
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Glucose stimulated insulin secretion of isolated islets
Mouse or human islets cultured in ECM dishes were stimulated by 2.8 mM glucose
for 1h followed by 16.7 mM glucose for 1h at 37oC. The supernatants were then
used to measure insulin or stored at -20oC. Insulin content was extracted with 0.18 N
HCl in 70% ethanol at 4 oC overnight or lysis buffer and determined by a human or
mouse insulin ELISA kit (ALPCO).
Immunocyto- and histo-chemical analysis
Isolated islets were fixed with 4% PFA/30 min. Mouse pancreases were isolated and
fixed with 4% PFA for 8h at 4oC and then paraffin embedded and cut into 4μm
sections. The slides were deparaffinized and immunostaining was carried out post
heat antigen-retrieval. The dishes or slides were incubated with the primary
antibodies; vessel marker - CD31 (ab28364, Abcam), Ang-2 (F-18, Santa Cruz
biotechnology, Inc.) proliferation -Ki67 (mouse-DAKO, human- Invitrogen), insulin
(DAKO) or apoptosis - TUNEL-AP kit for dishes or TUNEL-Rx mixture for slides
(Roche) followed by secondary antibodies; anti-rabbit, –rat, -goat Cy3 antibodies or
anti-guinea pig FITC or biotin (Jackson Immunosearch).
For morphometric analysis, ten sections (spanning the width of the pancreas) per
mouse were analysed as described before [37]. Pancreatic tissue area and insulin-
positive area were determined by computer-assisted measurements using a Nikon
MEA53200 (Nikon GmbH, Dusseldorf, Germany) microscope and images were
acquired using NIS-Elements software (Nikon). Mean percent ?-cell fraction per
pancreas was calculated as the ratio of insulin-positive and whole pancreatic tissue
area. ?-cell mass was obtained by multiplying the beta cell fraction by the weight of
the pancreas. For quantification of blood vessels we measured islet and vessel
areaby a Region of interest (ROI) tool using NIS-Elements software (Nikon).
Gene expression analysis
Total RNA was isolated from islets or cells with a Trizol extraction system (TriFast-
PEQLAB Biotechnology). For quantitative analysis of mRNA we used the Sybr
Green real-time PCR kit (Applied biosystems). 18s rRNA or cyclophilin were used as
internal housekeeping controls for all experiments and the products quantified by the
ΔΔCT method. Following primers were used: Mouse ANGPT1 Fw 5?-
GCCACCATGCTTGAGATAGG-3? and Rev 5?-TTCAAGTCGGGATGTTTGATT-3?,
ANGPT2 Fw 5?-CGCTGGTGAAGAGTCCAACT-3? and Rev 5?-ATTGTCCGAA-
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TCCTTTGTGC-3?, Tie-1/TIE Fw 5?-TCCCCCAGATCCTCAGTATG-3? and Rev 5?-
ATCTGGCTTGCGAAGTTTCA-3?, Tie-2/TEK Fw 5?-CCTTCACCAGGCTGATTGTT-
3? and Rev 5?-AATGCATTCCCCGGTATCTT-3?, CD31 Fw 5?-TGCTCTCGAA-
GCCCAGTATT-3? and Rev 5?-TGTGAATGTTGCTGGGTCAT-3?, NOS3 Fw 5?-
GACCCTCACCGCTACAACAT-3?and Rev 5?- CTGGCCTTCTGCTCATTTTC-3?,
ICAM-1 Fw 5?- TGGCGGGAAAGTTCCTGTTT-3? and Rev 5?- TAGGAGATGGG-
TTCCCCCAG-3?.Human ANGPT1 Fw 5?-ATCCCTCCGGTGAATATTGG-3? and Rev
5?-GAATAGGCTCGGTTCCCTTC-3?, ANGPT2 Fw 5?-GGCTGGGAAATGAGTT-
TGTT-3? and Rev 5?-CGGCTGTCCCTGTAAGTCCT-3?, Tie-1/TIE Fw 5?-GACTCC-
GAGATCCAGCTGAC-3? and Rev 5?-CCTGTCCACGTCTATCCACA-3?, Tie-2/TEK
Fw 5?-TGCTGTCATCAACATCAGCTC-3? and Rev 5?-TGTTGCCAAGCCTCAT-
AGTG-3?, CD31 Fw 5?-ATGATGCCCAGTTTGAGGTC-3? and Rev 5?-ACGTC-
TTCAGTGGGGTTGTC-3?, NOS3 Fw 5?- ACCCTCACCGCTACAACATC -3?and Rev
5?- GCTCATTCTCCAGGTGCTTC -3?, ICAM-1 Fw 5?-AACTGGACGTGGCC-
AGAAAA -3? and Rev 5?- ACAGAGGTAGGTGCCCTCAA -3?.
Western blot analysis
Islet and cell protein was extracted using RIPA lysis buffer and 25 ug protein was
loaded for western blot analysis. Actin, tubulin, cleaved caspase 3 (CST, Inc.), Ang-2
and ICAM-1 (SCBT, Inc.) were used at a 1:1000 dilution.
Statistical analysis
All values are expressed as the means ± SEM. The different groups were compared
by Students t test. A P value<0.05 was considered statistically significant.
Results
Islet vessel area increases in T2D
A causative correlation of islet vessel density and diabetes progression has been
suggested for years but it was not clearly known whether there are increased or
reduced vessels in islets in diabetes. Using autopsy pancreases, we quantified
vessel area within the pancreatic islets by CD31/PECAM-1, located on the surface of
endothelial cells and various blood cells. In full accordance with the recent study by
Brissova et al. [9], there was a 1.34-fold (p=0.055) increase in vessel to islet area in
T2D donors (n=10) compared to non-diabetic controls (n=6) (Fig.1A,B).The donor
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information is provided in suppl.table 1. We found no correlation in vessel density
and BMI of non-diabetic vs. diabetic donors (Fig.1C).
We further investigated the molecular basis of such changes in vessel density in a
model of diabetes progression in mice fed a high-fat high-sucrose diet up to 24
weeks. Angiogenic profile analysis after 8 weeks of high fat diet feeding, which
already affects glucose tolerance [38] showed upregulation in Ang-2 (1.2 fold,
p=0.05) and reduction of its receptor Tie-2 on endothelial cells compared to normal
diet fed mice but all other vessel markers (Tie-1, CD31) remained unchanged
(Fig.1D). Ang-1 is constitutively expressed at low levels, mainly by pericytes. In
mouse islets, its expression is less detectable and was unchanged (8 weeks) and
further downregulated with time of HFD feeding (data not shown) and a tendency in
humanT2D islets (Fig.1I, p=0.09).At 16 weeks of diet, when robust glucose
intolerance occurs together with ?-cell apoptosis[37, 39],both angiopoietin receptors
Tie-1and Tie-2were upregulated (1.5- and 1.8-fold, compared to ND control, Fig.1E)
and a clear upregulation in vessel markers analysed; Tie-1 (2.2-fold), Tie-2 (2.1-fold)
and CD31 (4.2-fold, p=0.06) was seen at 24 weeks (Fig.1F) together with an
increase in eNOS (2.2 fold, Fig.1G), involved in vessel dilation and ICAM-1 (2.5-
fold,Fig.1H), associated with leukocyte infiltration. No significant change in islet
insulin mRNA was seen in HFD mice compared to ND (Fig.S1A-C). VEGF-A
upregulation was more prominent at 16 weeks (Fig.S1D), as shown previously [17].
Thus, the angiogenic profile adapts with an increase in the angiopoietin receptors
Tie-1 and Tie-2 during vessel expansion and hypervascularization [6] during the
progression to T2D.
Human islets isolated from non-diabetic (n=4) and T2D (n=3) also showed
tendencies of higher expression of the vessel markers Tie-1 and Tie-2, but with a
high variation among the different donors.
Ang/Tie expression in isolated islets correlates with changes in vessel area
We further asked the question whether such increase in Tie-1/2 receptors is relevant
for ?-cell failure in T2D progression. Isolated mouse and human islets were used to
study the interactions between islet endothelial cells and islet function. To maintain
their physiological integrity, mouse and human isolated islets were cultured on
extracellular matrix coated dishes [40] and treated with a diabetic milieu of high
glucose (22.2 mM) and palmitic acid (0.5 mM) to mimic glucolipotoxicity or with a
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mixture of cytokines (cyto; IL1-β, IFN-ɣ and TNF-α). Mouse as well as human islets
showed impaired insulin secretion in response to glucose under glucolipotoxicity and
cytokines (Fig.2A,D).Though β-cell function was impaired in both conditions, we
found a clear reduction in the endothelial cell area only under cytotoxic and not
under gluco-lipotoxic conditions in both mouse (90% reduction,p<0.05) and human
(72% reduction,p<0.005) islets (Fig.2B,E) by double immuno-labelling forCD31
(endothelial cells) and insulin (?-cells; Fig.2C,F). The persistent vessels under
elevated glucose concentration may support the higher vessel density observation in
T2D, while cytokine treatment seems to be deleterious for both ?- and endothelial
cells.
In sync to the differences in vessel area under both diabetic conditions we also saw
an opposing trend in angiogenic expression when RNA analysis of Angiopoietin/Tie
angiogenic factors and CD31 was performed in the islets. CD31 expression was
upregulated under gluc/palm in human islets (2.2-fold) and downregulated under
cytokine treatment in both mouse (20% reduction,p<0.05) and human (47%
reduction,p<0.05) (Fig. 2G,J).
Ang-1, the agonist for the Tie-2, was downregulated under high glucose in human
and upregulated under cytokine treatment in mouse (6.2-fold, p<0.05) with only a
tendency in human islets. In contrast, Ang-2, the classical antagonist, was
upregulated under high glucose (3.2-fold in human, p<0.05) and down under
cytokines in both mouse (34%reduction, p<0.005) and human (56%reduction,
p<0.005; Fig.2H,K,M).
We found no significant differences in Tie-1 expression under high glucose/
palmitate in mouse but reduction in human islets under cytokine treatment. Tie-2 on
the other hand was down-regulated under high glucose and cyto in human islets
(Fig.2J) whereas it was upregulated under cytokine treatment in mouse islets
(Fig.2I). Although there were differences in Tie-1/Tie-2 receptor expression in mouse
and human islets, the ligands seem to follow a similar trend, with especially
significant Ang-2 upregulation in glucolipotoxicity and downregulation under
cytotoxicity- the latter paralleled with the regulation of CD31 .
45
Ang-2 over-expression basally impairs islet function but protects from
cytokine induced apoptosis in isolated islets
Seeing the upregulation of Ang-2 by glucolipotoxicity and its reduction by cytokines
in human islets, we were intrigued by the ambiguous role of Ang-2 and it?s direct or
indirect- via endothelial cells, effect on islet function in diabetes.
We initially used a downregulation approach to model the situation under cytokines
to see if there is an effect on islet survival or function. Downregulation of Ang-2 using
siRNA in human islets had neither an effect on glucose stimulated insulin secretion
nor on islet survival, although ICAM was upregulated by Ang-2 silencing in the
cytokine condition (Fig.S2A,B).
Ang-2 was then overexpressed to investigate whether antagonistic Tie2 signals
promote ?-cell function and survival. ?-cell specific Ang-2 upregulation was obtained
in islets isolated from mice expressing myc-tagged Ang-2 under the rat insulin
promoter conditionally via the reverse tetracycline activator (RIP-rtTA;Tet-O-Ang-
2)[16] and their culture in presence of doxycycline (Fig.3A). Ang-2 over-expression
remarkably impaired islet function at basal conditions (0.5-fold, p<0.005) as indicated
by the GSIS. In contrast, Ang-2 overexpression in cytokine treated mouse islets,
where GSIS was impaired, had no additive effect (Fig.3B).
Ang-2 not only has a dual role onTie-2 signaling with antagonistic as well as
agonistic effects, but also interacts with other receptors like the integrins[21, 22]. By
using a Tie-2 kinase inhibitor we and found that Tie-2 inhibition modulates the effects
of Ang-2 overexpression with reduction in ?-cell function at basal level and no effect
under cytokine treatment.
We also investigated the effect of Ang2/Tie2 on β-cell survival by analyzing
apoptosis by the TUNEL-assay (Fig.3C,D) and proliferation by Ki-67 staining
(Fig.S2C) in mouse islets. No effect on proliferation but protection from cytokine
induced apoptosis was seen with Ang-2 over-expression in mouse islets (41%
reduction, p<0.05, rtTA vs Ang2-rtTA (Fig.3D). Western blot analyses from treated
human islet lysates revealed a similar protection from cytokine induced apoptosis
with Ang-2 overexpression and Tie-2 inhibition, seen by lower cleaved caspase 3
(Fig.3G,H).
Along with effects on survival, Ang-2 overexpression and Tie-2 inhibition reduced the
expression of endothelial inflammatory marker ICAM-1 in mouse (Fig.3F) and human
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islets (Fig.3G,H). The effect of Tie-2 inhibition was reproducible by downregulation
ofTie-2 using siRNA in human islets (Fig.S2B) and in the mouse endothelial cell line
MS-1 (Fig.S2D). Tie-2 inhibition also resulted in reduced caspase 3 in endothelial
cells under cytotoxic conditions (Fig.S2E).
We could confirm the protective role of Ang-2 at cyototoxic conditions by the
opposite experiments. Downregulation of Ang-2 exacerbated inflammation, seen by
tendency of ICAM-1 upregulation in MS-1 cells (Fig.S2F) and human islets under
cytotoxic conditions (Fig.S2B).
Thus, inhibition of Tie-2 signaling at basal conditions impairs insulin secretion. In
contrast, when vessels are lost and Ang-2 expression is pathologically reduced by
cytokine treatment, its overexpression protects from cytokine induced apoptosis.
Further Ang-2 reduction potentiates the deleterious effects of cytokines. This
indicates towards a classic antagonistic role of Ang-2 on Tie-2 signaling.
Ang-2 over-expression leads to islet hypovascularization and β-cell failure in
response to HFD
Ang-2 was transiently upregulated under HFD and islets were hypervascularized
towards progression to T2D from 8 weeks to 24 weeks in mice, as well as under
glucolipotoxicity in vitro. Thus we set to investigate whether Ang-2 plays a role in
causing hypervascularization. Rip-rtTA;tet-O-Ang-2 and the control Rip-rtTA [16]
littermates were fed a high-fat high-sucrose diet and Ang-2 expression induced by
dox water for 16 weeks during the diet.β-cell-Ang-2 overexpression was confirmed in
the Rip-rtTA;tet-O-Ang-2 mice (Fig.S3A).During the 16 weeks feeding, HFD fed mice
gained 46% and ND fed mice gained 9.3% weight; there was no effect on weight
gain or food intake byAng-2 overexpression (Fig.S3B,C). HFD feeding lead to
impaired glucose and insulin tolerance, compared to ND fed mice. Ang-2
overexpression did not have any significant effect on glucose homeostasis under ND
or HFD (Fig.4A,B). HFD-feeding resulted in markedly higher fasted serum insulin in
controls (p<0.05) compared to the ND fed mice, sharp attenuation of insulin
secretion at 15 and30 min post i.p. glucose challenge(Fig.4C,p<0.05) and fully
abolished glucose stimulated insulin secretion (Fig.4D,p<0.005).
In line with a previous study [16], Ang-2 had a tendency for impairment in insulin
secretion under normal diet (p=0.06 vs. ND control), but the HFD mice showed
significantly higher insulin at 15 min post glucose injection (p<0.05). This did not
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reflect in changes of the stimulatory indices when compared to control ND or HFD
mice (Fig.4D). Therefore, it was confirmed that post-natal Ang-2 overexpression over
4 months in the ?-cells induces a minor impairment in insulin secretion under normal
diet but does not affect glucose homeostasis in response to HFD.
In WT mice HFD feeding resulted in an increased β-cell mass, compared to ND fed
mice (Fig.4E). Ang-2 over-expression had no effect at ND, but resulted in a lower β-
cell mass in the HFD (Fig.4E; p<0.05).
To address whether this reduction in β-cell mass might be stemming from an effect
on β-cell survival, we looked at proliferation and apoptosis, using Ki-67 and TUNEL-
assay, respectively. There was no significant difference in cell proliferation with diet
or Ang-2 expression (Fig.S3D) but increased β-cell apoptosis by Ang-2
overexpression (Fig.4F,p<0.05).
Under the normal diet, Ang-2 overexpression significantly increased the islet vessel
area, with more red blood cells filled vessels,(Fig.4G,p<0.05 vs rtTA ND), but a
significant hypervascularization occurred by Ang-2 under the HFD (p<0.05, vs rtTA
ND). The vascular changes induced by Ang-2 overexpression were also reflected by
mRNA Ang-1 downregulation (Fig.S3E) and upregulation of VEGF-A, Tie-1, Tie-2
and CD31 (Fig.S3F) under normal diet. HFD-induced endothelial inflammatory status
worsened with Ang-2 overexpression as seen by induction VCAM-1 and E-Selectin,
involved in leukocyte infiltration (Fig.S3H), which may directly lead to increased ?-
cell apoptosis, although a further functional decline did not occur.
Discussion
In this study we report an increased islet vessel area in T2D, which is in agreement
with a very recent study [9]. Such observation was rather surprising, since it has
been known for many years, that either a lower islet vessel density or a dysfunctional
endothelium is paralleled with diabetes progression.
The importance of a physiological balance of islet vascularization by adaptive
angiogenesis for β-cell mass expansion and function was questioned; shown to be
negligible on one [7, 8], but to be indispensible on the other hand [41]. Especially the
angiogenic factor VEGF-A promotes islet re-vascularization but directly impairs ?-cell
proliferation leading to a progressive loss in ?-cell mass in response to HFD [14, 17].
Also enhanced c-Kit receptor signaling improves islet vasculature and function in
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aged mice but elicits an inflammatory response and impairs islet function in response
to HFD [42]. VEGF-A [14, 15, 43] and several endothelial derived molecules,
collagen IV, thrombospondin-1 [44] and β1-laminin modulate islet function in vitro.
Endothelial- β-cell co-culture leads to the formation of pseudoislets [45], and
endothelial conditioned medium improves islet function [46]. Ang-1/Tie-2 signaling
promotes cell-cell contacts and contact to extracellular matrix [47, 48].
The Ang/Tie angiogenic cascade also participated in the adaptive increase in islet
vascularization with Ang-2 upregulation early during high fat/ high sucrose feeding in
mice and a persistent Tie receptor upregulation through 24 weeks of the
diabetogenic diet, together with upregulated vessel markers eNOS and CD31 at 24
weeks on a high fat diet.
Ang-2 induced vascular defects have been observed under hyperglycemia in chick
pancreases transplanted to STZ-treated mice [33]. This implies a role of Ang-2 in
inducing vascular anomalies. A resultant compensatory upregulation of Tie-1/-2 to
restore vessel stabilization [49] might be in play as seen at 24 weeks of HFD.
Ang/Tie were differentially regulated during HFD feeding and we hypothesized a role
for Tie signaling driving islet angiogenesis and function in T2D.
Ang-2 overexpression caused islet hypervascularization with a slight impairment in
insulin secretion under a normal diet, owing to the vascular defects causing irregular
blood perfusion. Despite this minor defect, there was no change in glucose tolerance
or insulin sensitivity in Ang-2 overexpressing mice.
On the other hand, in a HFD-induced obesity and insulin resistance model, ?-cell
specific Ang-2 overexpression led to hypovascularization, reduced β-cell mass with
increased β-cell apoptosis. From this data, one can clearly assume, that adaptive
hypervascularization is indeed necessary for the maintenance of ?-cell survival
under situations of higher insulin demand by the ?-cell.
Hypervascularization in T2D was supported by our findings in human autopsies and
mouse islets from HFD fed mice as well as in vitro studies in mouse and human
islets. Significantly upregulated levels of Ang-2 under glucolipotoxicity occurred
along with a persistent vessel area despite complete ablation of β-cell function.
Impairment in Tie-2 receptor signaling in hyperglycemia and elevated fatty acids via
Ang-1 downregulation has been reported [31]. Thus, the inverse regulation of Ang-
1/Tie-2 and Ang-2 in glucolipotoxicity points to a rather beneficial role of Tie-2
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signaling in islets. Glucolipotoxicity in β-cell failure is classically known [50, 51] but
the endothelial cell number is reduced in parallel to β-cell dysfunction in the culture
conditions we used.
While glucolipotoxicity induced CD31 expression together with an increase in Ang-2
in human islets, pro-inflammatory cytokines had a drastic effect on the endothelial
cells; with loss in CD31 and Ang-2 downregulation. We did not observe any effect on
?-cell survival upon modulating Ang-2 or Tie-2 in cultured islets under
glucolipotoxicity. But at the conditions of reduced islet vessel density reduced Ang-2
at cytokine treatment in vitro, Ang-2 overexpression significantly prevented cytokine-
induced apoptosis in mouse and human islets, pointing again to the importance of
maintaining physiological balance of angiogenic factors.
The protective effect of Ang-2 on cytokine induced apoptosis in islets and re-
vascularization has already been shown [32]. Now, this protection was also induced
by Ang-2, rather classically known to be pro-inflammatory, e.g. by sensitizing
endothelial cells to the effect of TNFα [21], but also shown to be anti-apoptotic in
lymphatic endothelial cells [52]. Ang-2 can assert beneficial effects in a Tie-2
independent manner through integrins [22]. In this study, Ang-2 triggered β-cell
apoptosis in HFD-induced diabetes, confirming its widely studied role in vascular
leakage [19, 20]. This was supported by the VCAM-1 and E-selectin upregulation in
islets from Ang-2-overexpressing HFD mice. In contrast, we also show the opposing
Ang-2 beneficial effects in vitro on apoptosis protection, which were indeed
confirmed by inhibiting Tie-2 in vitro in human islets and in the mouse endothelial cell
line. In contrast to its protective role on apoptosis, in vitro ?-cell function was
impaired by Ang-2 as well as by Tie-2 inhibition, affirming the antagonistic role of
Ang-2 in pathophysiological conditions and suggesting that an imbalance in
angiogenic factors is deleterious for homeostasis. Thus, a physiological balance of
Ang-2 is important for maintaining ?-cell survival and function, and may explain its
ambiguous effects.
In summary, our study shows that a functional vascular adaptation together with the
physiological preservation of Ang-2/ Tie-2 signaling under diabetic conditions is
indeed highly important for maintaining ?-cell survival and function.
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Figure legends
Figure 1: Islet vessel density increases in T2DM
(A)Representative images of pancreatic sections from non-diabetic controls (Con)
and type diabetic (T2D) donors, immune-labelled for CD31 (red) and insulin
(green).(B) Graphs showing ratio of vessel area to islet area,Con (n=6) and T2D
(n=10). (C) Plot showing correlation of vessel density to BMI. qPCR analysis of
isolated mouse islets from C57BL/6 WT mice kept on normal diet (ND) or high-fat
high-sucrose diet (HFD) Ang-2, Tie-1, Tie-2, CD-31 (D) 8 weeks, n=4/group (E) 16
weeks, n=9/group (F) 24 weeks, n=7/group (G)eNOS(H)ICAM-1 at 8, 16 and 24
weeks(I)qPCR analysis of isolated islets from non-diabetic (Con) and type 2 diabetic
(T2D) subjects, showing expression of Ang-1, Ang-2, Tie-1 and Tie-2. *p<0.05,
**p<0.005, HFD vs ND or T2D vs Con
Figure 2: Ang/Tie expression in isolated islets correlates with changes in
vessel area
Isolated WT mouse and human islets were cultured for 3 days in control condition,
11.1 or 5.5mM glucose for mouse (11.1) and human (5.5) or treated with diabetic
conditions of 22.2mM glucose + 0.5mM palmitic acid or mixture of cytokines 2 ng/mL
IL-1β, 1000U IFN-ɣ and TNF-α (cyto). (A,D) Islet insulin secretion is shown by the
stimulatory index assessed by 16.7/2.8 mM glucose stimulation, for mouse (n=4) and
human islets (n=5) (B,E) Graph shows a ratio of the quantification of vessel area to
islet area for mouse and human islets (C,F) The islets were fixed and  immune-
labelled for vessel (CD-31,red) and islet (insulin,green). qPCR analysis of treated
islets for (G-I) Mouse CD-31,Ang-1, Ang-2, Tie-1, Tie-2 (n=4-5) (J-L) Human CD-31,
Ang-1, Ang-2, Tie-1, Tie-2 (n=3-4). All genes have been normalized to PPIA or 18s
as housekeeping control.*p<0.05, **p<0.005, treated vs 11.1 or 5.5
Figure 3: Ang-2 over-expression impairs islet function but protects from
cytokine treatment in isolated islets
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Isolated islets from RIP-rtTA;tet-O-Ang-2 and RIP-rtTA mice were cultured for 3 days
in presence of 10μg/ml doxycycline for Ang-2 overexpression. Mouse or human
islets were cultured in 11.1 or 5.5mM glucose for mouse (11.1) and human (5.5) or
treated with diabetic conditions of 22.2mM glucose + 0.5mM palmitic acid or mixture
of cytokines 2 ng/mL IL-1β, 1000U IFN-ɣ and TNF-α  (cyto).(A) Western blot from
treated mouse islets shows myc-Ang-2 (B) Stimulatory index is represented by
normalisation to control condition (n=4) (C,D) Treated mouse islets fixed post-GSIS
and apoptotic cells detected by TUNEL-assay. Representative images from different
treatments are shown(E,F) qPCR data from mouse islets overexpressing Ang-2.
(G,H) Western blot showing myc-Ang-2, ICAM-1, cleaved caspase 3 and
actin/tubulin as housekeeping control, in human islets overexpressing Ang-2 by Ad-
Ang-2 or control Ad-GFP (MOI=50) or treated with 100 nM Tie-2 inhibitor for 72 h.
*p<0.05, **p<0.005, treated vs 11.1 or 5.5, #p<0.05, cyto+Ang-2 vs cyto
Figure 4: Ang-2 over-expression leads to islet hypervascularisation and β-cell
failure in response to HFD
β-cell specific overexpressing male Rip-rtTA;tet-O-Ang-2 (Ang2-rtTA) and Rip-rtTA
(rtTA) were kept on a normal diet (ND,n=8 mice) or high-fat high-sucrose diet
(HFD,n=19 mice) and Dox water (1mg/ml) for 16 weeks (A,B)Blood glucose levels
(mg/dL) from intraperitoneal glucose and insulin tolerance testsperformed at 16
weeks post HFD (C,D) Glucose stimulated insulin secretion, showing levels of serum
insulin and stimulatory index (E) β-cell mass analyses on pancreatic sections n=5-6
mice/group (F) Apoptotic cells labelled by TUNEL-assay, 10,000 β-cells/mouse, n=6
mice/group (G) Islet vessel area quantified by CD31/Insulin co-staining, from 100
islets/mouse, n=6 mice/group(H)Representative images from CD31 (red)/Insulin
(green) co-staining in mouse pancreatic sections. *p<0.05, **p<0.005 vs rtTA ND,
#p<0.05 vs rtTA HFD, §p<0.05 vs Ang2-rtTA ND
Table S1
Donor information – age, gender and BMI, of autopsies obtained from non-diabetic
and diabetic subjects,
Figure S1
qPCR analysis of isolated mouse islets from C57BL/6 WT mice kept on normal diet
(ND) or high-fat high-sucrose diet (HFD), Insulin genes, Ins1, Ins2 at (A) 8 weeks,
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n=4 (B) 16 weeks, n=3 (C) 24 weeks, n=4 (D) VEGF-A expression at 8, 16 and 24
weeks. All genes were normalized to PPIA
Figure S2
Human islets were transfected with siRNA (siAng-2 or siTie-2) and control siScr.
Islets were treated with diabetic conditions of 22.2mM glucose + 0.5mM palmitic acid
(GP) or mixture of cytokines 2 ng/mL IL-1β, 1000U IFN-ɣ and TNF-α  (cyto) for 72
h(A) Stimulatory index normalized to control condition, n=3 (B) Western blot
analyses of human islet lysates showing ICAM-1, cleaved caspase-3 and actin.
Isolated islets from RIP-rtTA;tet-O-Ang-2 and RIP-rtTA mice were cultured for 72 h in
presence of 10μg/ml doxycycline for Ang-2 overexpression and treated as above
(C)Treated islets fixed post-GSIS and colabelled with Ki-67/Insulin, Graph showing
%Ki-67 positive β-cells, n=3(D,E)Western blot analyses of MS-1 cells, transfected
with siRNA (siTie-2) and control siScr or  treated with 100nM Tie-2 inhibitor and
treated as above for 24 h. Blots show Ang-2, ICAM-1, cleaved caspase-3 and tubulin
or actin (F) qPCR data for Ang-2, CD31 and ICAM-1 in MS-1 cells transfected with
siAng-2 or control siScr and treated as above for 24 h, n=5,**p<0.005, *p<0.05 vs
siScr 5.5
Figure S3
β-cell specific overexpressing male Rip-rtTA;tet-O-Ang2 and Rip-rtTA were kept on a
normal diet (ND,n=8 mice) or high-fat high-sucrose diet (HFD,n=19 mice) and Dox
water (1mg/ml) for 16 weeks (A)Representative images from mouse pancreatic
sections showing dox induced β-cell specific Ang-2 expression (red) in mouse islets
(green) (B) %weight gain and (C) food intake/mouse/day over 16 weeks, *p<0.05,
**p<0.005 vs rtTA ND(D)Graph showing %Ki-67 positive β-cells in mouse pancreatic
sections, n=6 mice/group (E-H) qPCR analyses of islets isolated from rtTA and Ang-
2-rtTA, ND and HFD mice at 16 weeks, Ang-2, Ang-1, VEGF-A, Tie-1, -2, CD31,
ICAM-1, eNOS, VCAM-1, E-Selectin
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C. Discussion and outlook
This doctoral thesis includes three studies carried out on different aspects of
diabetes though the focus remains on islet vascularisation in T2D. In the first
published study, we showed the restoration of β-cell function and survival
from diabetic treatment, in response to 4 days treatment by the DPP4
inhibitor, linagliptin. Human islet cultured in extracellular matrix coated dishes
showed a basal proliferative capacity which was ablated and apoptosis was
induced upon treatment with high glucose, palmitate, cytokines and H2O2. The
efficacy of linagliptin on lowering blood sugar levels was established in 2010
after the Phase III clinical trial [1]. Sitagliptin was the first DPP4 inhibitor to be
approved by the FDA in 2006 [2]. Sitagliptin administration prevented
occurrence of overt diabetes in NOD mice [3] and linagliptin delayed the onset
of diabetes in NOD mice with reduced immune cell infiltration and preserved
β-cell mass temporarily but no effect later on [4]. Since, the discovery of DPP4
inhibitors, there have been studies on the efficacy of the drugs on the β-cell
survival, function and mass apart from its established effects on insulin
sensitivity [5]. Linagliptin and other DPP4 inhibitors are mostly administered in
combination with metformin and pioglitazone and not only as monotherapy [6].
GLP-1 actions are largely mimicked by the DPP4 inhibitor but not many
studies show its direct effects on islets unlike the well known beneficial effects
of GLP-1 on islets survival and function in mice as well as T2D subjects. In
this study, we also showed the stabilization of GLP-1 by increased active
GLP-1 in islet supernatants from the treated islets. Islet GLP-1 production is
prominent under diabetic conditions due to the increased expression of the
pro-hormone convertase PC1/3, responsible for cleavage of glucagon and
releasing GLP-1 [7]. Thus, the local GLP-1 provides a protective effect on β-
cells under diabetogenic conditions. The GLP-1 receptor expression is
decreased under hyperglycemia [8] and here we showed restored levels of
the receptor expression in human islets. DPP4 also cleaves SDF1α (1-68) to
its inactive form SDF1α (3-68), thus restoring its effects upon DPP4 inhibition.
We also showed reduction in levels of IL-6 and IL-1β, which are induced upon
cytokine milieu. In summary, we show that linagliptin has a protective effect
on β-cell turnover and function under diabetogenic conditions, which is
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mediated through stabilized GLP-1and anti-inflammatory/antioxidative stress
pathway.
In the second, unpublished study, we show the inhibition of CXCL10 in
protection from HFD induced insulin resistance and β-cell failure. We have
previously shown the upregulation of CXCL10 in diabetes and as a major
cytokine produced in the islets in T1D and T2D [9]. In this study we found anti-
CXCL10 antibody to improve glycemia, insulin secretion, insulin sensitivity
and β-cell survival and function in mice fed a high fat/high sucrose diet for 16
weeks. Moreover, we also saw reduced levels of inflammatory gene
expression in the peripheral tissues obtained from these mice. MDX-1100, a
highly specific CXCL10 neutralizing antibody blocks CXCL10 induced calcium
flux and cell migration with an estimated IC50 in the low nM range [10]. It
specifically inhibits CXCL10 and not CXCL9 or CXCL11, the other 2 ligands of
the classical receptor for CXCR3 [10]. TLR4 activation in obesity in response
to free fatty acids in adipose tissue, hypothalamic region of the brain as well
as pancreatic islets has been shown by many studies, thus linking the
metabolic and inflammatory bridge in obesity induced insulin resistance and
β-cell failure[11]. We have also shown TLR4 to be a binding partner for
CXCL10 and thus TLR4 antagonism serves as an attractive target for
improving the metabolic syndrome in the face of inflammation. FFAs induction
of TLR4 has received considerable attention as well and thus, in our study we
imply the antagonism of TLR4 as closing of a deleterious vicious cycle of
FFAs induced inflammatory induction in pancreatic islets as well as peripheral
tissues. It has entered the phase II clinical trial for rheumatoid arthritis and
was well-tolerated, demonstrated clinical activity and no drug related serious
adverse events were reported [12]. Though detected a >10-fold induction of
CXCL10 mRNA in isolated islets, immunostaining of the pancreas only
revealed in few β-cells positively stained for CXCL10 in islets from HFD mice
and expression pattern is very similar to CXCL10 expressing β-cells in
patients at recent onset of T1D [13]. This might be due the secretion of the
chemokine in the serum rather than accumulation in the cell and thus
undetectable by immunohistochemistry, similar to observations for IL-6 and
IL-1β [14, 15]. CXCL10 neutralization lead to reduced expression of IL-6 and
IL-1β probably due to mechanism through a feed-back, which reduces
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CXCL10 induced signalling. Only in the liver, IL-1β production failed to
decrease, pointing to a CXCL10 independent effect. In contrast, we did not
detect changes in inflammatory cytokine profile in response to HFD feeding in
the hypothalamus and thus, also no effect was seen by CXCL10 antagonism.
In summary, with the robust effect of the anti-CXCL10 antibody on glycemia,
insulin secretion and β-cell survival, we provide here a novel target for the
treatment of T2D.
Islet vascularisation in T2D has been the main focus of our studies. The islets
comprise of 1-2% of the total pancreatic mass but are provided with 10-15%
of the blood supply [39]. Thus, they are in close connection with the
endothelial cells and the surrounding extracellular matrix, forming a
specialized capillary network serving the tight regulatory role of islets in
glucose sensing and homeostasis. In our study we observed Ang-2 mediated
islet hypovascularization and apoptosis with reduced ?-cell mass in the HFD
setting. Thus, the adaptive hypervascularization is indeed necessary for the
maintenance of ?-cell survival under situations of higher insulin demand by
the ?-cell. Ang-2 lead to lower vascularization in contrast to the
hypervascularization induced by VEGF-A though in both models, there is
upregulation of endothelial inflammatory markers [16]. These differences
might be due to the residual state of the ?-cells in either case, which remain to
be impaired with hypervascularization causing impairment to a great extent
than hypovascularization. Our finding also supports that hypovascularized
islets go on functionally well [17] without exerting overt effects on progression
to ?-cell failure: despite the increase in ?-cell apoptosis which resulted in loss
of ?-cell mass, we didn?t observe a worsened diabetic phenotype despite
overexpression of Ang-2 over a prolonged period of 16 weeks. This might be
explained by the complex role of Ang-2 in physiology, being necessary for an
angiogenic response in some peripheral tissues and not in others. HFD
feeding also presents a metabolically complex setting with the inter-play of
several organs. It might be useful to assess the circulating levels of Ang-2 in
the serum to further explain this effect.
Ang-2 overexpression increased the islet vessel area under normal diet
conditions with slightly impaired insulin secretion observed in these mice upon
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glucose challenge. Ang-2 is known to induce vessel destabilization and this
probably also leads to higher ?-cell apoptosis under the HFD feeding in Ang-2
overexpressing mice.
Though in vitro Ang-2 seems to play even a protective role under a cytokine
milieu with reduced apoptosis in both Ang-2 overexpression as well Tie-2
inhibition. Thus the in vivo observation might be more an effect of the
physiological hypoxia induced by lower islet vascularisation associated with
necrotic cell death. In the current study we report an increased islet vessel
area in T2D, which is in agreement with a very recent study [18]. In presence
of VEGF-A, Ang-2 induces increased capillary diameter, remodeling of the
basal lamina and proliferation and migration of endothelial cells [19]. On the
other hand exogenous Ang-2 induces endothelial death and vessel regression
in absence of VEGF-A, which might be the explanation for Ang-2 induced
vessel regression observed upon HFD feeding. Systemic Ad-Ang-2 even
inhibits tumor growth by tumor microvessel regression in a mouse tumor
model [20]. This is a possible link to Ang-2 being associated with lower
vessels in diabetes. Anti-angiogenic therapies have been a central dogma of
tumor treatments for ages [21]. Ang-2 has been associated with a growing
mass of cells and vascularizing the tissue. This cannot be so easily mirrored
with the expanding ?-cell mass per se since the etiologies of the diseases are
completely different. ?-cell mass has a tremendous plasticity compared to an
ever growing tumor and while expanding ?-cell mass is a physiological
response to increased insulin demand, it does not necessarily lead to
diabetes. Therefore, islet blood flow regulation rather than robust
angiogenesis seems to play a central role in ?-cell mass expansion. On the
other hand a prolonged proliferation pressure on ?-cells may exert the
consequent hypervascularization observed in T2D and hypoxia may be the
cause for inducing vascularization rather than a consequence. This effect is
probably inhibited by Ang-2 overexpression and prevents ?-cell mass
expansion as we observed by lower ?-cell mass in Ang-2 expressing HFD
mice compared to the control HFD. Overall, Ang-2 prevents ?-cell mass
expansion and causes islet vessel regression in progression to T2D. Short
term effects of Ang-2 overexpression along with HFD feeding might lead to
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interesting results clarifying whether there are any effects of Ang-2 during the
first phase of insulin demand compensation.
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Abstract 
Aims/hypothesis. Inflammation participates in the pathophysiology of both type 1 (T1D) 
and type 2 diabetes (T2D) and leads to β-cell failure and impaired function. The pro-
inflammatory chemokine CXCL10 is expressed in islets in T1D and T2D and leads to β-
cell apoptosis and impaired function mediated through TLR4 signaling. In the present 
study we investigated whether CXCL10 antagonism improves glycemia, β-cell function 
and survival. 
Methods. C57BL/6J mice were fed a high fat/high sucrose diet (HFD) for 16 weeks and 
treated with an antibody to CXCL10 twice weekly. Glycemia was monitored and 
pancreas, liver, adipose tissue and hypothalamus were isolated and analyzed by IHC and 
RT-PCR after 16 weeks. 
Results. Anti-mouse CXCL10 antibody prevented diabetes progression; it improved 
glucose tolerance, insulin sensitivity and completely restored glucose stimulated insulin 
secretion in the HFD fed mice. 
While anti-CXCL10 treated HFD mice showed increased β-cell mass compared to 
normal diet (ND) controls, β-cells were unable to compensate for the higher insulin 
demand in response to the HFD in vehicle treated mice. Anti-CXCL10 treated mice 
showed no β-cell apoptosis under the HFD treatment; CXCL10 positive β-cells were 
found in HFD but not in ND or anti-CXCL10/HFD treated mice. IL-1β, IL-6 and 
CXCL10 mRNA in isolated islets were highly up-regulated in HFD treated mice, which 
was inhibited by anti-CXCL10. CXCL10 mRNA was up-regulated in epididymal fat and 
liver and attenuated by anti-CXCL10.  
Conclusions. Our results show that CXCL10 antagonism improved β-cell survival and 
function and support a potential role for anti-CXCL10 in the treatment of diabetes. 
 
Introduction 
Increased apoptosis resulting in decreased β-cell mass together with loss of function of 
the pancreatic β-cells are hallmarks of both, type 1 and type 2 diabetes (T1D/T2D). 
Therapies, which restore β-cell function and survival are urgently needed. A subclinical 
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inflammatory status has been observed in serum from patients with T2D. Pro-
inflammatory markers are elevated in insulin sensitive tissues such as muscle, liver 
adipose tissue and in pancreatic islets [1-6]. An overall impairment in glucose sensitivity 
in these tissues, stemming from and leading to both β-cell failure, indicates an 
inflammatory crosstalk involved in potentiating the disease progression. β-cells express 
high levels of pattern recognition receptors (PRR) and cytokine receptors, e.g. TLR2 and 
4 [7], IL-1R1 [8] and IL-6R/GPR30 [9]. In contrast to such high expression of PRRs, β-
cells express lower levels of anti-oxidative enzymes [10], rendering them sensitive to 
oxidative stress. 
Hyperlipidemia alone or in concert with hyperglycemia, so called “lipoglucotoxicity” can 
induce such pro-inflammatory state, shown in fat, where elevated free fatty acids lead to 
impaired insulin sensitivity, as well as in pancreatic islets, where prolonged 
lipoglucotoxicity initiates a vicious cycle in β-cell destruction [11], both mediated by 
TLR4 signaling [12, 13]. Consequently, downstream of TLR4, the constant activation of 
sub-clinical levels of pro-inflammatory cytokines can lead to a high local expression of 
markers involved in the acute immune response such as IL-1β, TNFα, IL-8, MCP-1 [14] 
and to disease development through activation of the classical apoptotic machinery [15]. 
Recent clinical trials showed that the neutralization of one single cytokine, IL-1β, a well-
known agent for its effects on β-cell dysfunction and destruction when exposed 
chronically in high levels, normalizes glycemia and reduces inflammation in patients with 
T2D [16-20]. 
CXCL10 was observed to play a causative role in diabetes development [21-23]. 
Increased CXCL10 serum levels are present in both T1D [24, 25] and T2D patients [26] 
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as well as in patients with high risk to develop T1D [24] and T2D [27]. It acts as a potent 
chemo-attractant for mononuclear cells, T-cells, B-cells and NK-cells. CXCL10 is 
present prior to the onset or at least at an early stage of the disease development, 
observed in the NOD mouse in the pancreas before signs of insulitis [28, 29]. CXCL10 is 
also expressed in β-cells in T1D [30] and T2D [5].  
Exposure of islets to CXCL10 in vitro at similar concentration as produced from diabetic 
islets leads to apoptosis and impairs β-cell function, this is mediated through TLR4 
signals. Pre-incubation with a neutralizing antibody to CXCL10 prevents from CXCL10 
induced apoptosis, confirming a CXCL10 specific effect [5]. Similarly, CXCL10 induces 
apoptosis in hepatocytes during liver injury, which is also mediated through TLR4 [31] 
and also causes apoptosis in the exocrine pancreas [32] as a possible mechanism for 
chronic pancreatitis. Also, an association of CXCL10 with both BMI and waist 
circumference [33] supports an interplay of FFAs with cytokines and chemokines and 
links obesity, inflammation and diabetes. CXCL10 is present at the onset of T2D in 
adults [27]. In young schoolchildren, serum levels of CXCL10, IL-6 and IL-18 correlate 
with obesity and insulin resistance [33] suggesting that CXCL10 may be an important 
factor in the development of insulin resistance and T2D in youth. 
These studies suggest that a pro-inflammatory milieu potentiates the complex 
pathological disturbances in metabolic diseases. We tested therefore, whether blocking 
CXCL10 signals using a neutralizing antibody to CXCL10 can restore normoglycemia in 
an animal model of diabetes, the high fat/ high sucrose fed mouse. Furthermore, we 
wanted to investigate whether blocking of CXCL10 can prevent the potentiation in 
cytokine production from insulin sensitive tissue and pancreatic islets. 
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METHODS 
CXCL10 antibodies. Two anti-CXCL10 were used in this study, anti-human CXCL10 
(MDX-1100, also known as BMS-936557) and anti-human CXCL10 that crossreacts 
with mouse species (referred to as anti-mouse CXCL10). Both antibodies and the 
corresponding isotype control antibodies were made as fully human monoclonal antibody 
in HuMab® or KM® transgenic mice and re-expressed as IgG1 (kappa) by recombinant 
DNA technology at Biologics Discovery California (BDC) of BMS (formally named 
Medarex). The mouse cross-reactive antibody was re-expressed as a mouse IgG1 to 
reduce the potential immunogenicity of the mAb in the mouse in vivo studies.  
Animals. Beginning at 6 weeks of age, C57BL/6J male mice originally obtained from 
The Jackson Laboratory (Bar Harbor, Maine) were fed either a normal diet (ND, 
Altromin GmbH & Co. KG #1320, containing 11, 65 and 24% calories from fat, 
carbohydrate and protein, respectively) or a high fat/high sucrose diet (HFD, “Surwit” 
Research Diets, New Brunswick, NJ, containing 58, 26 and 16% calories from fat, 
carbohydrate and protein, respectively [34] for 12-16 weeks. Mice were treated twice-
weekly with intraperitoneal (i.p.) injections of 10 mg/kg body weight mouse MDX1100 
or isotype control (mouse IgG1). Body weight and food consumption were monitored 
weekly.  
The following treatment groups were examined: (1) ND IgG (mice on normal diet and 
isotype control), (2) HFD IgG (mice on high fat/high sucrose diet and isotype control), 
(3) ND anti-CXCL10 (mice on normal diet and anti-mouse CXCL10), (4) HFD anti-
CXCL10 (mice on high fat/ high sucrose and anti-mouse CXCL10) in 3 independent 
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experiments. All animals were housed in a temperature-controlled room with a 12-h 
light/dark cycle and were allowed free access to food and water in compliance with the 
Guide for the Care and Use of Laboratory Animals, and the Bremen Senate in agreement 
with the National Institutes of Health animal care guidelines and §8 of the German 
animal protection law. 
Intra-peritoneal glucose and insulin tolerance tests. After 4, 8, 12 and 16 weeks of diet 
and treatment all animals underwent in vivo assays. Intraperitoneal glucose tolerance tests 
(ipGTT) and stimulated insulin secretion were performed after 12 h fasting and 
intraperitoneal insulin tolerance tests (ipITT) after 5h fasting as described before [35]. 
Stimulation index for insulin production was calculated by dividing the 30 min insulin 
(stimulated) by the 0 min value (basal). 
Homeostatic model assessment- insulin resistance. HOMA-IR was calculated using the 
method by Odegaard et al [36]: fasting insulin (ng/mL) x fasting glucose (mmol/L) = 
HOMA-IR. 
Histochemical analyses and β-cell mass. Pancreata were weighed, fixed and apoptosis 
and β-cell mass were analyzed as described previously [37]. CXCL10 analysis was 
performed through double-staining the sections with goat anti-mouse CXCL-10 antibody 
(Santa Cruz Biotechnology, Inc.) and guinea pig anti-insulin (DAKO), nuclei visualized 
with Vectashield Mounting Medium with DAPI (Vector Laboratories). 
Islet isolation and culture. Mouse islets from all groups were isolated as described 
previously [38] and cultured overnight in RPMI 1640 medium containing 11.1 mM 
glucose (PAA Laboratories GmbH, Cölbe, Germany). Human islets were isolated from 
four pancreata of healthy organ donors as described previously [39] and cultured in 
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CMRL-1066 medium [5]. Islets were exposed to 22.2 mM glucose plus 0.5 mM palmitate 
[40] with or without 10 µg/ml human MDX-1100 or 10 µg/ml human IgG. 
Cytokine expression analyses. Total RNA from epididymal fat pads, liver, 
hypothalamus and pancreatic islets was extracted from mice after 16 weeks of diet and 
treatment and isolated using peqGOLD TriFastTM (Peqlab) or RNeasy Mini Kit 
(Qiagen) for the hypothalamus. RT-PCR was performed using Power SYBR Green PCR 
Master Mix; Applied Biosystems). Primers see supplementary files. 
Calcium flux assay. Murine pre-B 300.19 cells overexpressing human CXCR3 were 
loaded with FLIPR Calcium 4 dye (FLIPR Calcium 4 kit, Molecular Devices, Sunnyvale 
CA). CXCL10 (Peprotech, Rocky Hill, NJ) at 3 nM was used to stimulate calcium flux. 
A titration of BMS-936557 from 13 pM to 600 nM was used to inhibit the response. A 
maximal calcium response was set with CXCL10 minus antibodies. A baseline response 
was established with buffer stimulation of cells without CXCL10. Calcium fluxes were 
read on the Flexstation (Molecular Devices, Sunnyvale, CA).  Data was graphed and 
analyzed with GraphPad Prism software, using nonlinear regression and sigmoidal dose-
response curves. 
Migration assay. Cells were loaded with Bis (acetoxymethyl) 2,2':6',2''-terpyridine-6,6''- 
dicarboxylate (BADTA) chemiluminescent migration reagent (PerkinElmer, Waltham, 
MA). CXCL10 at 3 nM was used to stimulate migration of cells through a filter 
containing 5 µm pores on Migration Plates from Neuro Probe (Gaithersburg, MD; Cat. 
ChemoTx 106-5). A titration of BMS-936557 from 13 pM to 600 nM was added to the 
cells. CXCL10 without antibody was used to establish maximal migration. Migration 
toward media alone without CXCL10 was used to measure background migration.  
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Following 2 hour incubation at 37 °C, migrated cells were detected by addition of 
DELFIA Europium solution to the lysed cells and detected by time resolved fluorescence 
on the Fusion (Perkin Elmer). Data was graphed and analyzed with GraphPad Prism 
software, using nonlinear regression and sigmoidal dose-response curves. 
Statistics. Samples were evaluated in a randomized manner by three independent 
investigators (PJ, NS and KM) who were blinded to the treatment conditions. Data are 
presented as means +/- standard error (SE) and were analyzed by paired, Student’s t test 
or by analysis of variance with a Bonferroni correction for multiple group comparisons. 
 
RESULTS 
Anti-CXCL10 antibodies block migration and calcium flux and have no effect on 
weight gain or food intake in mice. 
Generated antibodies used in this study recognize human (BMS-936557) and mouse 
CXCL10. To confirm the effect of the human and mouse antibodies, migration and 
calcium flux assays were performed. Anti-human CXCL10 antibody blocked migration 
(Suppl.Fig.1A) and calcium flux (Suppl.Fig.1B) of 300.19 cells transfected with human 
CXCR3 with an IC50 of 0.49 and 0.22 nM, respectively. When migration and calcium 
flux were measured using mouse CXCL10, the anti-mouse CXCL10 antibody had an 
IC50 of 32 (Suppl.Fig.1C) and 36 nM (Suppl.Fig.1D), respectively. In contrast, human 
and mouse IgG1 isotype controls had no effect. 
To assess the effect of specifically inhibiting CXCL10 during diabetes progression, we 
fed 6-week old C57BL/6J mice a normal (ND) or high fat/high sucrose diet (“Surwit”, 
HFD [37, 41]) and either injected peritoneally twice weekly an anti-CXCL10 antibody or 
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IgG isotype control for 16 weeks. Mice fed HFD gained more weight than the ND group, 
which reached significance already at 2 weeks (Fig.1A). The anti-CXCL10 antibody had 
neither an effect on food intake (Fig.1B) nor on weight gain (Fig.1A).  
Anti-CXCL10 improves glucose tolerance, insulin secretion and insulin sensitivity in 
mice. 
Insulin and glucose tolerance together with insulin secretion was measured after 4, 8, 12 
and 16 weeks of diet. Starting at 4 weeks on diet, untreated HFD mice developed glucose 
intolerance as measured by glucose tolerance test (ipGTT), while anti-CXCL10 treated 
mice had significantly lower glucose levels (not shown). After 12 weeks of diet, HFD 
mice developed elevated fasting glucose levels relative to ND mice (132±3 mg/dl for 
untreated HFD control mice vs. 66±3 mg/dl for ND control mice, p<0.05). This was 
prevented by anti-CXCL10 treatment in the HFD group (102±4 mg/dL, p<0.05). Anti-
CXCL10 improved glucose tolerance after 4, 8, 12 and 16 weeks of treatments and 
feeding. Fig.2A shows the results of the glucose tolerance tested after 16 weeks, HFD 
feeding increased glucose levels significantly at all time points, while anti-CXCL10 
treated mice show significantly improved glycemia. Area under the curve analysis 
revealed significantly lower glucose levels in the anti-CXCL10 treated HFD mice 
(Fig.2B, p<0.05).  
Since inhibition of CXCL10 led to an improvement in glycemic control, we tested the 
effect of anti-CXCL10 on insulin secretion. Fasted mice were injected with 2 g/kg 
glucose, and insulin secretion was measured before (0 min) and 30 min after glucose 
injection. In parallel to the HFD induced hyperglycemia (Fig.2A), mice were also 
hyperinsulinemic at the basal state (Fig.2C), compared to ND mice. After 16 weeks of 
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HFD, fasting insulin levels were 2.4-fold higher in untreated HFD mice, compared to ND 
(Fig.2C, p<0.05), glucose stimulated insulin secretion was almost fully abolished in this 
group, while anti-CXCL10 treatment in HFD mice restored GSIS (3.9-fold increased 
stimulatory index compared to untreated HFD control, p<0.001, Fig.2D), and also basal 
insulin levels were normalized (Fig.2D, 4.3-fold difference, p<0.001). 
Since the normalization of fasting insulin levels by anti-CXCL10 treatment in HFD mice 
could be a result of improved insulin sensitivity, we measured insulin tolerance in an 
ipITT (Fig.2E) and applied the analysis of homeostasis model assessment measure of 
insulin resistance HOMA-IR (Fig.2F).  
No significant differences in glucose levels were observed between treated and untreated 
animals of the ND group before and after the ipITT (Fig.2E). Untreated HFD-mice 
showed elevated glucose levels throughout the test compared to ND mice (p<0.05, Fig.2E 
at 0,15 and 30 min). In contrast, in the anti-CXCL10 treated HFD mice, glucose levels 
were unchanged compared to ND mice before and after the insulin injection  
HOMA-IR shown as the product of fasting insulin and fasting glucose [36] was elevated 
by the HFD from 4 weeks on, which gradually increased with length of diet (1.7-fold 
after 4 weeks and 4.3-fold increase in HFD compared to ND control, Fig.2F). Anti-
CXCL10 treatment significantly reduced HOMA-IR at all time points (Fig.2F, 3.7-fold 
decrease after 16 weeks).  
Anti-CXCL10 improves β-cell survival, restores β-cell mass and reduces intra-islet 
cytokine expression. 
We hypothesized that CXCL10 neutralization protects pancreatic β-cells and analyzed β-
cell apoptosis, β-cell mass and expression of pro-inflammatory cytokines in islets. 
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Previously, we reported increased β-cell mass in mice after 12 weeks of HFD despite the 
tendency for increased β-cell apoptosis at that time-point [37].  This was again confirmed 
in this study; HFD feeding induced a compensatory increase in β-cell mass in both 
control and anti-CXCL10 treated HFD groups (1.5- and 1.8-fold increase in both HFD 
control and HFD anti-CXCL10 groups vs. the respective ND groups, p<0.05, Fig.3A). In 
contrast to the findings after 12 weeks on diet, no increase in β-cell mass was observed in 
control mice after 16 weeks on HFD compared to those on ND (Fig.3B), but anti-
CXCL10 still restored β-cell mass compensation in HFD mice (2.3-fold increase vs. HFD 
non-treated, 1.7-fold increased vs. ND anti-CXCL10 treated). Such β-cell protection was 
also mirrored by TUNEL staining of pancreatic sections. HFD feeding for 16 weeks 
induced a 4.1-fold induction of TUNEL-positive β-cells, compared to ND (p<0.01), 
which was prevented by anti-CXCL10 treatment (2.7-fold reduction compared to HFD 
alone, p<0.01, Fig.3C,D). 
Anti-CXCL10 decreases pro-inflammatory cytokine expression in pancreatic islets, 
liver and fat 
Obesity and diabetes are highly correlated with increased inflammation; cytokines induce 
their own expression through an intracellular signaling cascade. Therefore, we tested 
whether inhibition of the chemokine CXCL10 by anti-CXCL10 treatment may inhibit 
expression of the major cytokine produced during obesity, IL-1β, IL-6 and TNFα as well 
as CXCL10 itself in islets, liver, fat and hypothalamus. 
CXCL10 expression was highly increased by HFD feeding over 16 weeks in islets, liver 
and adipose tissue, and anti-CXCL10 treatment normalized CXCL10 mRNA expression 
in all 3 tissues (Fig.4A,C,D). In islets, CXCL10 expression in the β-cell was confirmed 
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by immunocytochemistry, but we only detected few CXCL10-positive cells in each 
pancreas from the HFD group, and such CXCL10-positive cells were never observed in 
ND or anti-CXCL10 treated ND and HFD groups (Fig.4B). The cytokines IL-1β and IL-6 
were also upregulated by the high fat diet in islets, and also tend to increase in fat and 
liver and were normalized by anti-CXCL10, with the exception of IL-1β, which was not 
reduced by anti-CXCL10 in the liver (Fig.4D). TNFα was not increased by the HFD in 
islets, but was upregulated in liver and fat, where it was also normalized by anti-
CXCL10. Unexpectedly, neither HFD feeding nor anti-CXCL10 treatment induced any 
cytokine expression in the hypothalamus (Fig.4E). Such negative results were confirmed 
in additional sets of experiments in mice fed a HFD, and we again failed to measure any 
changes in cytokine mRNA expression in the hypothalamus (data not shown). 
Eventually, we tested the anti-CXCL10 antibody in human islets for its ability to reduce 
CXCL10 expression (Fig.4F). CXCL10 mRNA was upregulated by the diabetogenic 
milieu of glucose and palmitate, this was prevented by pre-treatment of human islets with 
anti-CXCL10 (Fig.4F).  
 
DISCUSSION 
MDX-1100, a highly specific CXCL10 neutralizing antibody blocks CXCL10 induced 
calcium flux and cell migration with an estimated IC50 in the low nM range [42] has 
entered clinical trials for the treatment of two classical inflammatory diseases, ulcerative 
colitis (UC) [42] and rheumatoid arthritis, where MDX-1100 was well-tolerated, 
demonstrated clinical activity and no drug related serious adverse events were reported. It 
specifically inhibits CXCL10 and not CXCL9 or CXCL11, the other 2 ligands of the 
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classical receptor for CXCR3 [42]. 
Based on our previous data showing CXCL10 as a major cytokine produced by pancreatic 
islets in response to a diabetic milieu in T1D as well as in T2D, we tested the mouse 
specific anti-CXCL10 antibody for its efficacy to protect from diabetes progression in the 
high fat/ high sucrose fed mouse model. Anti-CXCL10-antibody improved glycemia, 
insulin secretion, insulin sensitivity and β-cell survival and function. Also, CXCL10 
mRNA levels as well as inflammatory genes produced downstream the TLR4-NFκB 
pathway, which were increased in response to the HFD in pancreatic islets, in fat and liver, 
were significantly decreased by the anti-CXCL10 treatment. 
Many studies show TLR4 activation in response to free fatty acids [12, 13, 43] in fat, brain 
as well as in pancreatic islets, which supports the link of obesity and metabolic diseases, 
where inflammation occurs in insulin sensitive tissue and promotes insulin resistance as 
well as in islets, where β-cell failure occurs. Thus TLR4 antagonism has been identified as 
a potent target to improve glucose metabolism [12], although TLR4 was also shown to 
contribute to the proinflammatory state in models of T1D [44]. Direct binding of FFA to 
TLR4 has not been identified, but a recent study suggests fetuin as a binding partner of 
FFA to TLR4 [45]. In line with this observation, fetuin-A levels are associated with a 
higher risk of developing T2D [46]. The present study clearly shows HFD induced 
cytokine and chemokine production in insulin sensitive tissue and in pancreatic islets. The 
fact that neutralization of the chemokine CXCL10 normalizes glycemia suggests that the 
activation of the inflammatory response is causative for the development of insulin 
resistance and impaired β-cell function. Cytokines and chemokines are produced 
downstream of TLR4. This opens a vicious cycle when chronically produced in obesity 
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[23]. CXCL10 was thereby most prominently induced in islets in HFD treated mice and its 
production totally reduced by CXCL10 antagonism, supporting the effect of its own 
production-stimulation. Although we have observed a >10-fold induction of CXCL10 
mRNA in isolated islets, immunostaining of the pancreas only revealed in few β-cells 
positively stained for CXCL10. Such CXCL10 positive β-cells were only detected in islets 
from the HFD fed mice, and expression pattern is very similar to CXCL10 expressing β-
cells in patients at recent onset of T1D [30]. One explanation could be that CXCL10 is 
secreted and thus could not always be detected by immunohistochemistry.   
IL-1β and IL-6 were also highly induced in islets by HFD feeding, both shown to be 
implicated in the regulation of glycemia [47, 48], while TNFα levels were not affected, 
which is in line with previous observations in human islets in vitro [6]. CXCL10 
neutralization led to reduced production of IL-1β, IL-6, most likely through a feed-back 
mechanisms, which reduces CXCL10 induced signalling. 
Analysis of insulin sensitive tissue revealed HFD-induced production of CXCL10, IL-1β, 
IL-6 and TNFα in fat and liver, which was significantly reduced by CXCL10 antagonism. 
Only in the liver, IL-1β production failed to decrease, pointing to a CXCL10 independent 
effect. 
In contrast, we did not detect changes in inflammatory cytokine profile in response to HFD 
feeding in the hypothalamus and thus, also no effect was seen by CXCL10 antagonism. In 
contrast, previous studies show upregulation of inflammatory gene expression including 
CXCL10 in the hypothalamus after 20 weeks HFD feeding. Here, a different diet, rich in 
fat but not in glucose was used. Also, hypothalamic NFκB activation was shown in 
numerous elegant studies in response to obesity [49]. Inhibition of NFκB signalling 
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improved glycemia and insulin sensitivity, but downstream NFκB targets were not 
investigated in these studies [49]. These previous studies support an involvement of the 
hypothalamus in the regulation of glycemia, but cytokine expression occurs in waves in 
response to the HFD [50]. Although inflammatory cytokines are increased in obesity and 
were measured in numerous studies in serum of overweight and obese patients as a 
predictive marker for the development of T2D, it remains still largely unknown if 
cytokines, especially IL-1β, which mainly functions locally in the inflamed tissue, 
contribute to the inter-organ crosstalk in obesity. Despite high levels of IL-1β and 
CXCL10 mRNA in the insulin sensitive tissue, we could only measure marginal levels in 
the serum, which were mostly under the detection limit of the assays and thus, no 
significant differences were obtained. Such measures would support a local and no 
systemic role of cytokines/ chemokines in sensitive tissue. Nevertheless, because of the 
presence of soluble IL-1β binding proteins and its rapid degradation despite immediate 
freezing of the serum [51], we cannot exclude false-negative measures in the mouse 
serum. 
In summary, with the robust effect of the anti-CXCL10 antibody on glycemia, insulin 
secretion and β-cell survival, we provide here a novel target for the treatment of T2D. The 
effect of CXCL10 neutralization in vitro in human islets and in vivo in experimental 
models of T1D supports the protection on the level of the β-cell [52, 53]. 
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FIGURE LEGENDS 
Figure 1. CXCL10 neutralization does not influence weight gain  
Mice were fed a normal (ND) or high fat diet (HFD) and injected twice weekly with 
either IgG (control) or anti-CXCL10 at 10 mg/kg for 16 weeks. Body weight/mouse (A) 
and average weekly food intake/5 mice in a cage (B) are from 3 independent experiments 
from 13 mice/group. Data show mean ± SE. *p<0.05 HFD vs. ND, same treatment 
 
  19 
Figure 2. CXCL10 neutralization improves insulin secretion and sensitivity in mice.  
Mice were fed a normal (ND) or high fat diet (HFD) and injected twice weekly with 
either IgG (control) or 10 mg/kg anti-CXCL10 for 16 weeks.  (A) Glucose was measured 
during a glucose tolerance test (ipGTT) after 16 weeks before (0 min) and after glucose 
injection (1g/kg BW) and area under the curve (B, AUC) of the glucose tolerance tests 
calculated for each treatment group during the 16 weeks of diet and treatment. (C) Insulin 
secretion was measured during the ipGTT before (0 min) and after glucose injection (30 
min, 2g/kg BW) and (D) the insulin stimulatory index calculated as a ratio of stimulated 
(30 min) over basal (0 min) insulin. (E) Insulin tolerance test (ipITT) with an 
intraperitoneal injection of 0.75 U/kg insulin after 5 h fast performed after 16 weeks and 
(F) Homeostatic Model Assessment–Insulin Resistance (HOMA-IR) of mice as a product 
of fasting insulin and glucose levels during 16 weeks of diet and treatment. Data are 
means ± SE from 3 independent experiments from 13 mice/group. *p<0.05 HFD vs. ND, 
same treatment, **p<0.05 anti-CXCL10 vs. IgG, same diet 
 
Figure 3. CXCL10 neutralization restores β-cell mass and improves β-cell survival.  
(A,B) β-cell mass per pancreas was calculated as the product of the relative cross-
sectional area of β-cells (determined by quantification of the cross-sectional area 
occupied by β-cells divided by the cross-sectional area of total tissue) and the weight of 
the pancreas from the mice after 12 (A) and 16 (B) weeks of diet. 10 sections per mouse 
spanning the width of the pancreas were included in the analysis. (C,D) Triple staining 
for TUNEL in red, insulin in green and DAPI in blue was performed on fixed, paraffin 
embedded islet sections (Magnification x250). White arrows indicate TUNEL positive β-
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cells (triple-stained, D). Results are expressed as percentage of TUNEL-positive β-cells ± 
SE. The mean number of β-cells scored was 10,790 for each treatment condition (C).  
*p<0.05 HFD vs. ND, same treatment, **p<0.05 anti-CXCL10 HFD vs. IgG HFD. 
 
Figure 4. Anti-CXCL10 decreases pro-inflammatory cytokine expression in 
pancreatic islets, liver and fat 
(A,C,D,E,F) mRNA expression of CXCL10, IL-1β, IL-6 and TNFα in isolated islets (A), 
epidydimal fat (C), liver (D) and hypothalamus (E) after 16 weeks of diet and treatment 
with IgG or anti-CXCL10 analyzed by RT-PCR. Data are means of the relative 
quantification normalized to one control ND mouse, respectively ± SE from 9 (C-F) or 3 
(A) mice/group. *p<0.05 HFD vs. ND, same treatment, **p<0.05 anti-CXCL10 vs. IgG, 
same diet. (B) CXCL10 expression in islets was confirmed by immunocytochemistry of 
mouse pancreases from the 4 treatment groups stained for insulin in green and CXCL10 
in red. The white arrow points to CXCL10 positive β-cells. 
(F) Human islets were exposed to the mixture of elevated glucose (22.2mM) and 
palmitate (0.5mM) for 3 days and treated with anti-CXCL10-Ab (10 µg/ml). mRNA 
expression of CXCL10 was analyzed by RT-PCR. Data are means of the relative 
quantification normalized to untreated control islets from 4 independent experiments 
from 4 different human islet donors ± SE. 
 





Supplemental data: 
Mouse specific primers of the following sequences were designed to perform RT-
PCRs: 
 
Tubulin - product length: 250 bp 
Forward: GTTGGCCAGGCTGGTGTCCAG 
Reverse: CTGTGATGAGCTGCTCAGGGTGG 
 
Cyclophilin - product length: 210 bp 
Forward: GTGGTCTTTGGGAAGGTGAA 
Reverse: TTACAGGACATTGCGAGCAG 
 
CXCL10 - product length: 158 bp 
Forward: GTGAGAATGAGGGCCATAGG 
Reverse: TTTTGGCTAAACGCTTTCATT 
 
IL6 - product length: 88 bp 
Forward: CCAGAGATACAAAGAAATGATGG 
Reverse: ACTCCAGAAGACCAGAGGAAAT 
 
IL1β  - product length: 249 bp 
Forward: CAGGCAGGCAGTATCACTCA 
Reverse: AGCTCATATGGGTCCGACAG 
 
TNFα - product length: 138 bp 
Forward: ACGCCATGGATCTCAAAGAC 
Reverse: AGATAGCAAATCGGCTGACG 
 
Human specific TaqMan (Applied Biosystems) assays were used to perform RT-
PCRs: 
CXCL10: Hs00171042_m1 
cyclophilin: Hs99999904_m1 
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isolated islets through GLP-1 stabilization
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The DPP-4 Inhibitor Linagliptin Restores -Cell
Function and Survival in Human Isolated Islets
Through GLP-1 Stabilization
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Context: Inhibition of dipeptidyl peptidase-4 (DPP-4) is a potent strategy to increase glucose-
dependent insulinotropic polypeptide and glucagon like peptide 1 (GLP-1) induced insulin secre-
tion in diabetes. It is important to know whether new drugs approved for the treatment of type
2 diabetes have direct effects on the -cell.
Objective: Herein we investigated the effect of linagliptin, a novel DPP-4 inhibitor, on -cell func-
tion and survival.
Design: Human islets were exposed to a diabetic milieu (11.1–33.3 mM glucose, 0.5 mM palmitate,
the mixture of 2 ng/mL IL-11000 U/mL interferon-, or 50 M H2O2) with or without 500 ng/mL
IL-1 receptor antagonist (IL-1Ra) or 30–50 nM linagliptin.
Results: Linagliptin restored -cell function and turnover, which was impaired when islets were
exposed to elevated glucose, palmitate, cytokines, or H2O2. Pretreatment with IL-1Ra was similarly
effective, except against H2O2 treatment. Nitrotyrosine concentrations in islet lysates, an indicator
of oxidative stress, were highly elevated under diabetic conditions but not in islets treated with
linagliptin or IL-1Ra. Linagliptin also reduced cytokine secretion and stabilized GLP-1 in islet
supernatants.
Conclusions: We show that the novel DPP-4 inhibitor linagliptin protected from gluco-, lipo-, and
cytokine-toxicity and stabilized active GLP-1 secreted from human islets. This provides a direct
GLP-1 mediated protective effect of linagliptin on -cell function and survival. (J Clin Endocrinol
Metab 98: E1163–E1172, 2013)
Dipeptidyl peptidase 4 (DPP-4) is a ubiquitous cell-mem-brane protein enzyme responsible for cleaving and in-
activating both incretins, glucagon like peptide 1 (GLP-1)
and glucose-dependent insulinotropic polypeptide (1),
which are released by cells in the small intestine after the
ingestion of food and which potentiate glucose-stimulated
insulinsecretion(2).Patientswithtype2diabetes (T2D)have
impaired insulin secretion and chronic hyperglycemia, and
the effect of the incretins is significantly reduced (3).
Incretin-based therapies such as injectable GLP-1 re-
ceptor agonists or DPP-4 inhibitors are established treat-
ments for T2D because of their glucose-dependent stim-
ulation of insulin secretion, their inhibition of glucagon
secretion, and their intrinsic lack of risk for hypoglycemia
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(4), although an increased risk for pancreatitis has been
discussed recently (5).
Long-term clinical effects of incretin-based drugs on the
-cell are still speculative (6). However, numerous in vivo
and in vitro studies in rodents show that GLP-1 increases
-cell mass, proliferation (7–9), and -cell neogenesis
(10). GLP-1 inhibits -cell apoptosis in human islets (11–
13), and a protective effect was also observed in islets
isolated from patients with T2D (14).
Accordingly, stabilizing GLP-1 by DPP-4 inhibition re-
stores glycemic control in diabetic animal models (2) and
improves -cell survival, replication, and neogenesis in the
diabetic mouse and rat streptozotocin model (15, 16) and
in the VDF diabetic rat (17).
The direct effect of DPP-4 inhibitors on human -cells
has not been investigated yet. Thus, the aim of this study
was to test whether a DPP-4 inhibitor would restore -cell
function and survival under diabetogenic conditions in
human islets and whether cytokine production from islets
under such conditions is affected. For our studies, lina-
gliptin, a xanthine-based, highly potent, and long-acting
DPP-4 inhibitor was used, which has recently been ap-
proved for the treatment of T2D (18, 19). IL-1 receptor
antagonist (IL-1Ra), which improves -cell survival and
function by neutralizing IL-1 (20, 21), was used as a
positive control for a -cell protective effect. In the present
study, we provide evidence that linagliptin improves -cell
survival and function in human islets through stabilization
of GLP-1, which is secreted during islet culture.
Materials and Methods
Cell culture
Human islets were isolated from 8 pancreata of healthy organ
donors at Lille University and cultured in CMRL-1066 medium
as described previously (22, 23). Islet purity was greater than
95% as judged by dithizone staining (if this degree of purity was
not achieved by routine isolation, islets were handpicked). For
long-term in vitro studies (96 hours), islets were cultured on
extracellular matrix-coated plates derived from bovine corneal
endothelial cells (Novamed Ltd, Jerusalem, Israel), allowing the
cells to attach to the dishes and spread, preserving their func-
tional integrity (24). In parallel, islets were cultured in suspen-
sion dishes, treated for 72 hours, and fixed with Bouin’s solution.
Islet sections were prepared as described previously (21).
Human islets were exposed to a diabetic milieu [11.1–33.3
mM glucose or 5.5 mM glucose0.5 mM palmitic acid, the
mixture of 2 ng/mL recombinant human IL-1 (R&D Systems,
Minneapolis, Minnesota)] 1000 U/mL recombinant human in-
terferon (IFN)- (Pepro Tech, Rocky Hill, New Jersey) for 72
hours or 50 M H2O2 for 8 hours with or without 500 ng/mL
IL-1Ra, 10 nM-1 M linagliptin, 200 nM sitagliptin, 100 nM
exendin-(9–39) (Bachem, Bubendorf, Switzerland) or 0.5 nM
GLP-1 (Sigma, St Louis, Missouri). Compounds were added 1
hour before the exposure to the diabetogenic conditions and
throughout the culture. Palmitic acid was dissolved as described
previously (25).
Ethical approval for the use of islets had been granted by the
Ethical Committee of University of Bremen. We received the
islets from the European Consortium For Islet Transplantation.
Whenever an islet isolation fails to be suitable for transplanta-
tion, centers provide them for islet research. Thus, these research
projects comply with National Institutes of Health regulation
Public Health Service 398, exemption 4. Human pancreata were
harvested from brain dead donors, according to the European
and national regulations for organ procurement. Donors or their
family members gave written consent to donate organs for trans-
plantation and research, all documented by the transplantation
centers. Human islet isolations were performed with the ap-
proved protocols of the centers.
Cell turnover
For detection of -cell apoptosis, 100 human islets were cul-
tured in suspension dishes, treated for 72 hours, and fixed with
Bouin’s solution. Islet sections were prepared as described pre-
viously, deparaffinized, rehydrated, and incubated with 20
mg/mL proteinase K (Roche Applied Science, Mannheim, Ger-
many) for 15 minutes at 37°C before staining. In parallel, islets
on extracellular matrix (ECM)-coated dishes were fixed using
4% paraformaldehyde and insulin costained with apoptosis an-
alyzed by the terminal deoxynucleotidyl transferase-mediated
deoxyuridine 5-triphosphate nick-end labeling (TUNEL) tech-
nique according to the manufacturer’s instructions (in situ cell
death detection kit, TMR red; Roche Applied Science) (26).
For the analysis of -cell proliferation, fixed islets on ECM-
coated dishes were incubated overnight at 4°C with mouse an-
tihuman Ki67 (Invitrogen, Carlsbad, California), followed by
detection with donkey-rat Cy3-conjugated antibody (Jackson
ImmunoResearch Laboratories, West Grove, Pennsylvania). In-
sulin was analyzed by anti-guinea pig insulin antibody (Dako,
Glostrup, Denmark) followed by detection with donkey anti-
guinea pig fluorescein isothiocyanate-conjugated antibody
(Jackson ImmunoResearch Laboratories). Islets and islet sec-
tions were embedded in Vectashield mounting medium (Vector
laboratories, Burlingame, California). Fluorescence was ana-
lyzed using a Nikon Eclipse Ti-U inverted research microscope
(Nikon GmbH, Dusseldorf, Germany), and images were ac-
quired using NIS-Elements software (Nikon).
Glucose-stimulated insulin secretion (GSIS)
Islets used to perform glucose-stimulated insulin secretion
experiments were kept in culture medium on matrix-coated
dishes. For each independent experiment, 20 islets were plated
and exposed to the treatment conditions as indicated above. For
acute insulin release, islets were washed and preincubated (30
minutes) in Krebs-Ringer bicarbonate buffer (KRB) containing
2.8 mM glucose. The KRB was then replaced by KRB containing
2.8 mM glucose for 1 hour (basal), followed by an additional 1
hour incubation in KRB containing 16.7 mM glucose (stimu-
lated). Islets were lysed in lysis buffer and whole islet protein
measured by bicinchoninic acid protein assay (Pierce, Rockford,
Illinois/Thermo Scientific, Rockford, Illinois). Insulin was deter-
mined using a human insulin ELISA kit (ALPCO, Windham,
New Hampshire) and normalized to whole-islet cell lysate pro-
tein content.
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Determination of nitrotyrosine
Nitrotyrosine concentration in human islets after the 4-day
culture period was determined in islet cell lysates by an adapted
ELISA method as previously described (27, 28). At the end of the
incubation, islets (a total of 30 islets/condition) were washed in
PBS, suspended, and lysed for 40 minutes on ice in lysis buffer [20
mM Tris acetate (pH 7.0), 0.27 M sucrose, 1 mM EDTA, 1 mM
EGTA, 50 mM NaF, 1% Triton X-100, 5 mM sodium pyro-
phosphate, 10 mM -glycerophosphate (all Sigma Aldrich)] con-
taining 1 protease and a phosphate inhibitor cocktail (Thermo
Scientific). Protein concentrations of islet cell lysates were de-
termined by bicinchoninic acid protein assay, and whole-cell
lysates were stored at 80°C until assayed. The standard curve
samples were prepared by dissolving 1 mg/mL BSA (Sigma) in 50
mmol/L KH2PO4. After the addition of 1 mmol/L tetranitrome-
than, the dilution was incubated for 30 minutes at 37°C and
adjusted to pH 10, and the amount of nitrotyrosine present was
measured at 430 nm, and moles nitrotyrosine for each mole
protein were calculated directly using the Beer-Lambert law ( 
4300 M1/cm1) (29). Standards of 0.05–0.6 pmol/L were pre-
pared. Maxisorp ELISA plate (number 353279; BD, Franklin
Lakes, New Jersey) was coated with standards and samples in
coating buffer (50 mmol/L Na2CO-NaHCO3 buffer at pH 9.6)
overnight at 4°C, washed 6 times with 0.05% Tween 20 in PBS,
and incubated with IgG monoclonal antinitrotyrosin (Upstate
Biotechnology, Lake Placid, New York/Millipore, Bedford,
Massachusetts) for 2 hours at room temperature, washed, and
incubated for 45 minutes at 37°C with horseradish peroxidase-
conjugated goat antimouse (Zymed, San Francisco, California)
and washed again. For the peroxidase reaction, 100 L tetram-
ethyl-benzidine microwell peroxidase substrate (Sigma) was
added for 10 minutes at room temperature, and the reaction was
stopped by adding 50 L stop solution (BD Opty Kit B/0.5 M
H2SO4, BD) and read at 492 nm on a microplate reader. Con-
centration of nitrotyrosine was normalized to whole-protein
content of islet lysates.
Determination of cytokines, GLP-1, and DPP-4
After the 4-day culture period, human islet supernatants were
measured for cytokine release using the human proinflammatory
tissue culture kit (Meso Scale Discovery; Rockville, Maryland).
Total and active human GLP-1 was detected by the same assay
platform (Meso Scale Discovery).
DPP-4 activity was detected using H-Ala-Pro-7-amido-4-tri-
fluoromethylcoumarin (purchased from Bachem) in a 200-mM
stock solution in dimethylformamide, which was diluted 1000-
fold with water before the assay. The assay itself was performed
in black flat-bottom, 96-well plates by mixing 50 L of the di-
luted substrate (final concentration in the assay 100 M), 25 L
of supernatant, and 25 L of assay buffer (100 mM Tris-HCl;
100 mM NaCl, pH 7.8). The plate was then incubated at room
temperature for 1 hour and fluorescence was measured at exci-
tation/emission wavelengths of 405/535 nm. For standards, 20
L of appropriate compound dilutions was prepared in assay
buffer (compound stock solutions in dimethylsulfoxide final
concentration in the assay 1%).
RNA extraction and RT-PCR analysis
Total RNA was isolated from cultured human islets by the
Trizol method (peqGOLD TriFast; PeQLab, Erlangen, Ger-
many). For quantitative analysis, we used the Applied Biosys-
tems StepOne real-time PCR system (Applied Biosystems, Foster
City, California) with a commercial kit [Power SYBR Green PCR
master mix or TaqMan(R) Fast Universal PCR master mix for
TaqMan assays; Applied Biosystems]. Primers used were 5-
ggctggtcatatggagggta-3/5-cagggctttggagatctgag-3 (DPP-4),
5-agagccaacgtcaagcatct-3/5-ctttagcttcgggtcaatgc-3 [stromal
cell-derived factor-1a (SDF1)], 5-tccccaactcctgagttcac-3/5-
acatcctcgacggcatctcag-3 (IL-6), 5-tcctcctcggcttcagacac-3/5-
gtaattggccgccacacagt-3 (GLP-1 receptor) 5-gttggccaggctggt-
gtccag-3/5-ctgtgatgagctgctcagggtgg-3 (tubulin), 5-
ccaaccgcgagaagatga-3/5-ccagaggcgtacagggatag-3 (actin),
5-tacgggtcctggcatcttgt-3/5-ccatttgtgttgggtccagc-3 (cyclo-
philin), and 5-aaacggctaccacatccaag-3/5-cctccaatggatc-
ctcgtta-3 (18S). The TaqMan(R) gene expression assays (Ap-
plied Biosystems) were used for IL-1, IL-8, cyclophylin, and
tubulin.
Statistical analysis
Immunostainings were evaluated in a randomized manner by
2 investigators (P.S., S.L.), who were blinded to the treatment
conditions Data are presented as means  SEM and were ana-
lyzed by a paired Student’s t test or by ANOVA with a Bonferroni
correction for multiple group comparisons.
Results
Linagliptin, sitagliptin, and IL-1Ra improve -cell
survival
Loss of -cells by apoptosis and decreased -cell mass
have been recognized as major pathological factors for the
progression of diabetes. We tested the hypothesis whether
linagliptin can protect -cells from damage induced by
diabetogenic conditions. Isolated human pancreatic islets
were exposed for 4 days to increasing glucose concentra-
tions (5.5, 11.1, 33.3 mM), 0.5 mM palmitate, the mixture
of cytokines (2 ng/mL IL-11000 U/mL IFN-), or 50
M H2O2, for 8 hours, conditions that caused -cell ap-
optosis and almost complete loss of proliferation. Islets
were pretreated with 500 ng/mL IL-1Ra, which has been
shown to improve -cell survival (21), or with 50 nM
linagliptin, which was added 1 hour before the diabeto-
genic conditions and maintained throughout the 4-day
culture. At basal culture conditions of 5.5 mM glucose for
4 days, 10–1000 nM linagliptin had no influence on -cell
turnover (data not shown). Elevated glucose concentra-
tions, free fatty acids, cytokines, and oxidative stress in-
duced -cell apoptosis (2.5-, 3.6-, 3–1-, 3.7-, and 4.5-fold
induction by 11.1 and 33.3 mM glucose and by 0.5 mM
palmitate, IL-1IFN-, and H2O2, respectively, P 
.001, Figure 1A) in isolated human islets, compared with
control incubations. This was reversed by pretreatment
with IL-1Ra as well as with linagliptin. IL-1Ra reduced
apoptosis 2.5, 2.0-, 2.1-, and 3.0-fold in 11.1 and 33.3
mM glucose, palmitate, and IL-1IFN-, respectively
(P  .01), but in H2O2, only a tendency but no significant
doi: 10.1210/jc.2013-1029 jcem.endojournals.org E1165
The Endocrine Society. Downloaded from press.endocrine.org by [${individualUser.displayName}] on 04 October 2015. at 12:16 For personal use only. No other uses without permission. . All rights reserved.
protective effect was observed (Figure 1A). Fifty nano-
moles of linagliptin reduced apoptosis 2.3-, 3.8-, 2.0-,
2.5-, and 2.1-fold in all diabetogenic conditions (P 
.01, Figure 1A).
Human islets on the ECM-coated dishes had a very
limited capacity to proliferate in culture (0.4%  0.1%
Ki67/insulin double positive cells at 5.5 mM glucose basal
condition). A diabetic milieu even further reduced this
proliferative capacity (2.2-, 2.8-, 2.3-, 1.7-, and 1.9-fold
reduction by 11.1 and 33.3 mM glucose and by 0.5 mM
palmitate and IL-1IFN- when incubated for 4 days
and H2O2 when incubated for 8 hours, respectively, com-
pared with control, P  .01, Figure 1B). In contrast, IL-
1Ra and linagliptin restored prolif-
eration (4.3-, 5.8-, 4.0-, and 3.1-fold
induction by IL-1Ra and 4.8-, 6.8-,
4.4-, 2.1-, and 4.1-fold by linagliptin
in 11.1 and 33.3 mM glucose, in 0.5
mM palmitate, IL-1IFN-, and
H2O2, respectively, compared with
vehicle, P  .01, Figure 1B). IL-1Ra
had no protective effect on -cell
proliferation under H2O2 exposure.
This was also confirmed in mouse is-
lets, which were exposed for 8 hours
to 50 M H2O2 with or without 500
ng/mL IL-1Ra. Apoptosis was in-
duced 3.6-fold by H2O2, whereas IL-
1Ra failed to show any protective ef-
fect (data not shown).
To exclude a matrix-dependent
effect, we cultured isolated human
islets in suspension culture dishes,
exposed them for 3 days or 8 hours
(H2O2) to the above-described dia-
betogenic milieu and analyzed -cell
apoptosis in Bouin-fixed, paraffin-
embedded islet sections. A similar in-
duction of -cell apoptosis was ob-
served by all diabetogenic culture
conditions, and linagliptin signifi-
cantly reduced -cell apoptosis (1.9-,
2.0-, 2.3-, 1.5-, and 1.2-fold in 11.1
and 33.3 mM glucose, 0.5 mM
palmitate, IL-1IFN-, and H2O2,
compared with vehicle, P  .01; Fig-
ure 1D). Sitagliptin, another DPP-4
inhibitor tested in the same experi-
ments, had similar protective effects
(Figure 1D; 1.4-, 1.9-, 4.7-, 2.5-, and
1.3-fold reduction of -cell apopto-
sis in 11.1 and 33.3 mM glucose, 0.5
mM palmitate, IL-1IFN-, and
H2O2, P  .01).
Linagliptin improves -cell function and inhibits
oxidative stress
In addition to its protective effect on -cell survival,
linagliptin improved GSIS in islets after long-term culture
of 4 days. In control conditions, there was a 4-fold stim-
ulatory index when glucose was increased from 2.8 mM to
16.7 mM glucose (Figure 2D). All diabetogenic culture
conditions significantly reduced GSIS (P  .01; Figure 2,
A and D). At basal glucose, neither IL-1Ra (Figure 2, B and
D) nor linagliptin (Figure 2, C and D) increased the stim-
Figure 1. DPP-4 inhibition improves -cell survival. Human pancreatic islets were cultured on
ECM-coated dishes (A and B) or in suspension (C and D) at 5.5 mM (control), 11.1 or 33.3 mM
glucose, 0.5 mM palmitate, or 2 ng/mL IL-1 per 1000 IU IFN- for 96 hours (A and B) or 72h (C
and D) or at 50 M H2O2 for 8 hours (A–D) in the absence (control) or presence of IL-1Ra (500
ng/mL) or linagliptin (50 nM). Apoptosis was analyzed either directly in the dishes (A) or in
paraffin-embedded islet sections (C and D: nuclei) by the TUNEL assay. Proliferation was analyzed
in the dishes (B) by the Ki67 antibody. All specimens were double stained for insulin. Results are
means  SEM of the TUNEL- or Ki67-positive -cells, normalized to control conditions at 5.5 mM
glucose (in absolute numbers: 0.4% TUNEL and 0.37% Ki67 positive -cells at 5.5 mM glucose
on the extracellular matrix and 1.0% TUNEL positive -cells at 5.5 mM glucose in suspension
culture). The average number of -cells counted was 4175 for each treatment group from 3
different experiments from 3 different organ donors. C, A representative staining picture of a
palmitate-treated human islet (upper panel, 200 magnification) with 2 TUNEL-positive nuclei
(lower panel, 600 magnification). *, P  .05 compared with vehicle-treated control at 5.5 mM
glucose; **, P  .05 compared with vehicle under the same treatment condition.
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ulatory index, but under the diabetogenic conditions,
GSIS was highly improved (1.2-, 1.4-, 1.9-, 2.3-, and 1.8-
fold by IL-1Ra, Figure 2, B and D, and 1.9-, 2.5-, 2.1-, 2.4-,
and 2.5-fold by linagliptin, P  .05, Figure 2, C and D).
To investigate the underlying mechanisms of the pro-
tective effect of the DPP-4 inhibitor, we hypothesized that
changes in nitrotyrosine, a marker for oxidative stress,
may occur during the long-term exposure with diabeto-
genic conditions. Nitrotyrosine production in islets during
the 4-day culture period was measured and normalized to
whole protein content of the islet lysate. The nitrotyrosine
content was increased by glucose, palmitate, cytokine, and
H2O2 exposure (P  .05; Figure 2E). Both IL-1Ra and
linagliptin decreased nitrotyrosine under glucose, palmi-
tate, and cytokine treatment (P  .05) but not under con-
ditions of H2O2 (Figure 2E).
Linagliptin stabilizes GLP-1 in the supernatants of
human islet cells
Because the main effect of DPP-4 is to stabilize GLP-1,
we next investigated whether total and active GLP-1 levels
in the culture medium were increased by linagliptin treat-
ment. Diabetogenic conditions (increasing glucose con-
centrations and cytokines) induced accumulation of total
GLP-1 (Figure 3A) in the islet supernatants, and linagliptin
(30 nM) pretreatment resulted in an approximately 2-fold
higher total GLP-1 (Figure 3A) and an approximately
3-fold higher active GLP-1 (Figure 3B) in all conditions.
Levels of total and active GLP-1 were unchanged by IL-
1Ra (data not shown).
Next, the effect of linagliptin on the stabilization of an
exogenously added GLP-1 concentration was investi-
gated. One hour after linagliptin (30 nM) treatment, 0.5
nM GLP-1 (a concentration similar to the secreted total
GLP-1 from the islets treated with linagliptin) was added
to the islet culture medium and immediately measured.
Rapid degradation of GLP-1 was observed during the cul-
ture (Figure 3, C and D), whereas the addition of linaglip-
tin inhibited such degradation of GLP-1. The total (Figure
3C) and active GLP-1 (Figure 3D) accumulated during
culture in the linagliptin-treated islet supernatants, which
did not occur in the nontreated islets.
GLP-1 stabilization was accompanied by restored
GLP-1 receptor levels. In confirmation with earlier studies
(30, 31), GLP-1 receptor levels were decreased in response
to glucotoxicity and cytokine exposure, compared with
untreated control. In contrast, 30 nM linagliptin increased
GLP-1 receptor levels in all diabetogenic conditions (Fig-
ure 3E). To further prove whether the effect of linagliptin
is GLP-1 dependent, we pretreated linagliptin with exen-
din-(9–39), an established inverse agonist of the GLP-1
receptor (32, 33). Although 30 nM linagliptin was effec-
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tive in improving GSIS under cytokine exposure, the ad-
dition of 100 nM exendin-(9–39) inhibited the linagliptin
effect (Figure 3F). To prove that linagliptin was active, we
also measured DPP-4 activity in the islet cell supernatants.
As expected, linagliptin inhibited DPP-4 activity in culture
(Figure 3G). The potential GLP-1-SDF1 synergism
strongly promotes -cell survival (34). Because SDF1 is
another substrate of DPP-4 (35) and an important pro-
survival factor for -cells (36), we tested whether the in-
creases in GLP-1 concentration and the reduction in
DPP-4 activity by linagliptin are also paralleled with
SDF1 mRNA production. Linagliptin strongly increased
SDF1 under basal as well as under diabetogenic condi-
tions (P  .05, Figure 3H), whereas glucose and palmitate
themselves or IL-1Ra treatment of the islets had no such
effect on SDF1 (Figure 3H).
Linagliptin inhibits cytokine secretion and
production from islets under diabetogenic
conditions
Because proinflammatory cytokines and chemokines
are elevated under a diabetogenic milieu, we tested
whether IL-1Ra and linagliptin exert their protective ef-
fects through an inhibition of cytokine secretion. Cytokine
and chemokine secretion into the culture medium was
measured simultaneously by the Meso Scale Discovery
technique and mRNA production by RT-PCR. The dia-
betogenic milieu, which included elevated glucose concen-
trations and palmitate, significantly increased IL-1 se-
cretion (Figure 4A) and mRNA production (Figure 4B),
whereas IL-6 (Figure 4, C and D) and IL-8 (Figure 4, E and
F) were increased by the cytokine mixture IL-1 and
IFN-, but no significant effect was observed in the other
diabetogenic conditions. Although IL-1Ra and linagliptin
had no effect on the minimal basal IL-1 secretion and
production during the 4-day culture period, they signifi-
cantly decreased both IL-1 secretion and mRNA pro-
duction (Figure 4, A and B) under diabetogenic conditions.
Similarly, IL-6 and IL-8, which were elevated in response
to IL-1/IFN-, were decreased by IL-1Ra and linagliptin
(Figure 4, C–F).
Discussion
Orally administered DPP-4 inhibitors prevent the rapid
cleavage of GLP-1 and thus increase levels of active
GLP-1, resulting in increased insulin and reduced gluca-
gon secretion, lowered glucose, and reduced glycosylated
hemoglobin levels by 0.5%–1.0% (2). Linagliptin im-
proves glycemic control both as monotherapy (37) and in
combination therapy, eg, with metformin (38) or piogli-
tazone (39), and also improves insulin sensitivity (39).
DPP-4 inhibitors mimic many of the actions ascribed to
GLP-1 in rodents including preservation of -cell mass
through stimulation of cell proliferation and the inhibition
of apoptosis in rodents (15–17).
In addition to glucose-dependent insulinotropic poly-
peptide and GLP-1, many gastrointestinal hormones, neu-
ropeptides, cytokines, and chemokines are substrates for
DPP-4 (40), including C-X-C motif chemokine 10
(CKCL10) and SDF1, both of which are involved in im-
mune regulation and the influence the inflammatory re-
sponse and have been associated with the regulation of
-cell turnover in diabetes (23, 34). Because cytokines and
chemokines are crucial for the survival of pancreatic
-cells (41), it remained to be investigated whether DPP-4
inhibitors in culture directly affect -cell survival and
function.
In the present study, the DPP-4 inhibitor linagliptin
effectively restored proliferation, survival, and -cell func-
tion in a diabetic milieu. The concentrations of 30–50 nM
we used were higher than the average maximum concen-
tration plasma levels but also could be obtained in patients
taking therapeutic doses of linagliptin (42). At all concen-
trations up to 1 M, which is 1000-fold the IC50 of the
human enzyme, linagliptin did not affect -cell survival at
basal conditions in culture.
Human -cells in culture have only a very limited, if any
(42), capacity to proliferate. Here we found 0.4% prolif-
erating -cells under basal conditions when islets were
plated on ECM-coated dishes, and proliferation was fur-
ther decreased by diabetogenic conditions of chronically
elevated glucose, free fatty acids, cytokines, or H2O2.
Linagliptin improved cell survival by decreasing apoptosis
and maintained cells at a steady state level, even under
diabetogenic conditions.
The protective linagliptin effect seen in this study was
mediated by the stabilization of GLP-1 in the islet super-
natants, in which total as well as active GLP-1 levels were
restored and accumulated during islet culture, providing a
similar mechanism as seen in vivo.
Active GLP-1 can be produced from islets (43). The
-cells express prohormone convertase 1/3, which cleaves
preproglucagon peptide to generate GLP-1. -Cells are an
established islet source of secreted GLP-1 (44–47) and
may provide a local protective paracrine effect for -cell
regeneration under diabetic conditions, especially during
-cell injury (34). Sorted human -cells also express pro-
hormone convertase 1/3, but the GLP-1 content could not
be detected, and thus, it was assumed that -cells do not
produce GLP-1 (48), although it was found to be secreted
from the rodent -cell line, INS-1E (49).
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We found high levels of active GLP-1 (3 ng/mL from
50 islets over 4 days of culture) were secreted from human
islets and accumulated only in the presence of a DPP-4
inhibitor, whereas high DPP-4 activity could be measured
only in the absence of linagliptin.
GLP-1 is accumulated in the medium during the 4-day
culture period and provides in turn a paracrine protective
effect on the -cell. Diabetogenic conditions, eg, the cy-
tokine cocktail IL-1/IFN-, enhanced IL-6 production.
This was counteracted by linagliptin and paralleled with
increased GLP-1 in the medium. It can thus be hypothe-
sized that higher GLP-1 concentrations in the culture me-
dium in turn inhibits IL-6 production; this would provide
a negative feedback loop to the IL-6 effect to induce GLP-1
in islets (44).
Hyperglycemia and a diabetic milieu decrease expres-
sion of -cell GLP-1 receptors in vivo and in vitro (30, 31,
50). In contrast, diabetogenic conditions significantly in-
creased total GLP-1 release from cultured islets. This was
also observed in islets from patients with T2D (45) and
from diabetic Psammomys obesus
(47), which show higher GLP-1 se-
cretion than nondiabetic controls.
Slightly reduced GLP-1 secretion
after a meal in patients with impaired
oral glucose tolerance and more se-
verely impaired GLP-1 secretion in
type 2 diabetic patients was observed
(52), although controversial results
have been obtained in various stud-
ies (53). Differences occur between
tissue-specific GLP-1 levels and
whether total or active GLP-1 was
measured (54). It is possible that
reduced GLP-1 in T2D patients is
the result of elevated plasma DPP-4
activity (55), which can be induced
by chronic hyperglycemia and is
paralleled with reductions of active
GLP-1 (56).
Linagliptin strongly reduced
DPP-4 activity in the human islet su-
pernatant and stimulated GLP-1 sta-
bility. Active DPP-4 rapidly degrades
SDF1(1–68) to inactive SDF1(3–
68) (57), and thus, more active
SDF1 is available upon DPP-4 in-
hibition. In turn, SDF1 acts like a
cytokine and induces its own pro-
duction (34). This explains the in-
creased SDF1 mRNA levels with
linagliptin treatment, found in the
present study.
The regulation of DPP-4 in diabetes has not been fully
clarified, and both increased (55, 56) and decreased (58)
DPP-4 activity has been reported in patients with diabetes.
DPP-4 release from adipose tissue is higher in obese indi-
viduals and correlates with parameters of the metabolic
syndrome, in which DPP-4 directly impairs insulin signal-
ing in fat and muscle cells (59). Elevated glucose exposure
leads to enhanced DPP-4 activity and mRNA expression in
endothelial cells (51). Also, in human islets, we detected
elevated DPP-4 mRNA in response to elevated glucose and
palmitate, whereas linagliptin inhibited this induction
(data not shown). One could speculate that in islets under
diabetogenic conditions, there is more DPP-4 produced,
which inactivates the elevated GLP-1, and thus, it cannot
fulfill its functions.
Recent human studies investigating the long-term treat-
ment with vildagliptin on -cell function were somehow
disappointing because after the washout periods, the ob-
served -cell-sparing effectsdisappeared, thusquestioning
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Figure 4. Linagliptin inhibits cytokine secretion from islets under diabetogenic conditions.
Human pancreatic islets were cultured on extracellular matrix-coated dishes at 5.5 mM (control),
11.1 or 33.3 mM glucose, 0.5 mM palmitate, or 2 ng/ml IL-1 per 1000 IU IFN- for 96 hours in
the absence (control) or presence of IL-1Ra (500 ng/mL) or linagliptin (50 nM). B, D, and F, mRNA
was isolated from treated islets after 4 days and RT-PCR analyses of IL-1 (B), IL-6 (D), and IL-8 (F)
were performed. The levels of gene expression were normalized to tubulin and cyclophilin (with
similar results) and presented as change of control. Cytokine and chemokine secretion of IL-1
(A), IL-6 (C), and IL-8 (E) from the culture medium of the same islets were analyzed in a multiplex
assay (Meso Scale Discovery). Results are means  SEM from 3 independent experiments from 3
donors. *, P  .05 compared with vehicle treated control at 5.5 mM glucose; **, P  .05
compared with vehicle under the same treatment condition.
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the disease-modifying potential of this drug (6). However,
it remains to be elucidated whether this is caused by a
limited tissue penetration in vivo or limited availability of
the drugs in islets.
In summary, we show that linagliptin has a protective
effect on -cell turnover and function under diabetogenic
conditions, which is mediated through stabilized GLP-1
and an antiinflammatory/antioxidative stress pathway.
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